70476-82-3 | Mitoxantrone dihydrochloride

Packsize	Purity	Availability	Price	Discounted Price
1mg	97%	in stock	$15.00	$10.00
10mg	97%	in stock	$21.00	$15.00
25mg	97%	in stock	$41.00	$29.00
50mg	97%	in stock	$74.00	$52.00
100mg	97%	in stock	$76.00	$53.00
250mg	97%	in stock	$106.00	$74.00

Description

• Catalog Number: AB76230
• Chemical Name: Mitoxantrone dihydrochloride
• CAS Number: 70476-82-3
• Molecular Formula: C22H30Cl2N4O6
• Molecular Weight: 517.4027999999998
• MDL Number: MFCD00242943
• SMILES: OCCNCCNc1ccc(c2c1C(=O)c1c(C2=O)c(O)ccc1O)NCCNCCO.Cl.Cl

Computed Properties

• Complexity: 571
• Covalently-Bonded Unit Count: 3
• Heavy Atom Count: 34
• Hydrogen Bond Acceptor Count: 10
• Hydrogen Bond Donor Count: 10
• Rotatable Bond Count: 12

Literature

• ABC-transporter blockage mediated by xanthotoxin and bergapten is the major pathway for chemosensitization of multidrug-resistant cancer cells.

  Toxicology and applied pharmacology 20171215

• Disease modifying therapies for relapsing multiple sclerosis.

  BMJ (Clinical research ed.) 20160822

• Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.

  Archives of toxicology 20160101

• The age factor for mitoxantrone's cardiotoxicity: multiple doses render the adult mouse heart more susceptible to injury.

  Toxicology 20150302

• Single pre-treatment with hypericin, a St. John's wort secondary metabolite, attenuates cisplatin- and mitoxantrone-induced cell death in A2780, A2780cis and HL-60 cells.

  Toxicology in vitro : an international journal published in association with BIBRA 20141001

• The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.

  The Journal of pharmacology and experimental therapeutics 20130201

• A case report of acute myeloid leukemia after liver transplantation.

  Acta haematologica 20130101

• Enhanced expression of membrane transporter and drug resistance in keloid fibroblasts.

  Human pathology 20121101

• Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

  Haematologica 20121101

• Anthraquinone derivative O,O'-bis-(3'-iodopropyl)-1,4-dihydroxyanthraquinone modulates immune response and improves experimental autoimmune encephalomyelitis.

  International immunopharmacology 20121001

• cRGD-functionalized mPEG-PLGA-PLL nanoparticles for imaging and therapy of breast cancer.

  Biomaterials 20121001

• Dual-functional liposome for tumor targeting and overcoming multidrug resistance in hepatocellular carcinoma cells.

  Biomaterials 20121001

• A label-free method for studying DNA sequence recognition of mitoxantrone based on resonance light-scattering technique.

  The Journal of antibiotics 20121001

• Oleic acid decreases BCRP mediated efflux of mitoxantrone in Caco-2 cell monolayers.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20121001

• Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy.

  Lung cancer (Amsterdam, Netherlands) 20121001

• Cadmium inhibits ABCG2 transporter function in BeWo choriocarcinoma cells and MCF-7 cells overexpressing ABCG2.

  Placenta 20121001

• OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance.

  Biochemical pharmacology 20120915

• Mitoxantrone repression of astrocyte activation: relevance to multiple sclerosis.

  Brain research 20120914

• Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.

  Urologic oncology 20120901

• Flow cytometry-based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia.

  Cytometry. Part B, Clinical cytometry 20120901

• Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.

  Haematologica 20120901

• Surface functionalization of mesoporous silica nanoparticles controls loading and release behavior of mitoxantrone.

  Pharmaceutical research 20120901

• Outcome of children with refractory anaemia with excess of blast (RAEB) and RAEB in transformation (RAEB-T) in the Japanese MDS99 study.

  British journal of haematology 20120901

• The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.

  Molecular cancer therapeutics 20120901

• Breast cancer resistance protein (BCRP/ABCG2) localises to the nucleus in glioblastoma multiforme cells.

  Xenobiotica; the fate of foreign compounds in biological systems 20120801

• New use for an old drug: inhibiting ABCG2 with sorafenib.

  Molecular cancer therapeutics 20120801

• Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter.

  Cancer research 20120715

• Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature.

  Rheumatology international 20120701

• Utilizing inherent fluorescence of therapeutics to analyze real-time uptake and multi-parametric effector kinetics.

  Methods (San Diego, Calif.) 20120701

• Treatment of experimental brain metastasis with MTO-liposomes: impact of fluidity and LRP-targeting on the therapeutic result.

  Pharmaceutical research 20120701

• Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG).

  British journal of haematology 20120701

• Mitoxantrone-iron oxide biodistribution in blood, tumor, spleen, and liver--magnetic nanoparticles in cancer treatment.

  The Journal of surgical research 20120601

• Successful treatment of recurrent malignancy-associated hemophagocytic lymphohistiocytosis with a modified HLH-94 immunochemotherapy and allogeneic stem cell transplantation.

  Medical oncology (Northwood, London, England) 20120601

• A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding.

  The AAPS journal 20120601

• Management of children with multiple sclerosis.

  Paediatric drugs 20120601

• Failure event types and prognostic factors after node-positive breast cancer in patients treated by adjuvant chemotherapy: impact on follow-up.

  Bulletin du cancer 20120601

• [Docetaxel plus prednisone versus mitoxantrone plus prednisone as first-line chemotherapy for metastatic hormone-refractory prostate cancer: long-term effects and safety].

  Zhonghua wai ke za zhi [Chinese journal of surgery] 20120601

• Castration-resistant prostate cancer: many treatments, many options, many challenges ahead.

  Cancer 20120515

• Anthracenedione-methionine conjugates are novel topoisomerase II-targeting anticancer agents with favorable drug resistance profiles.

  Biochemical pharmacology 20120501

• Effective down-regulation of breast cancer resistance protein (BCRP) by siRNA delivery using lipid-substituted aliphatic polymers.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20120501

• Spectroscopic investigations of the molecular interaction of anticancer drug mitoxantrone with non-ionic surfactant micelles.

  The Journal of pharmacy and pharmacology 20120501

• [Percutaneous coronary intervention in a patient with acute myeloid leukemia].

  Deutsche medizinische Wochenschrift (1946) 20120501

• Real-time cell analysis of human cancer cell lines after chemotherapy with functionalized magnetic nanoparticles.

  Anticancer research 20120501

• Noninvasive in vivo optical assessment of blood brain barrier permeability and brain tissue drug deposition in rabbits.

  Journal of biomedical optics 20120501

• Immunotherapies in neurologic disorders.

  The Medical clinics of North America 20120501

• A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.

  Blood 20120426

• Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20120411

• Clinical spectrum of CNS aquaporin-4 autoimmunity.

  Neurology 20120410

• Coordination bonding based pH-responsive albumin nanoparticles for anticancer drug delivery.

  Dalton transactions (Cambridge, England : 2003) 20120407

• Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation.

  Bone marrow transplantation 20120401

• Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia.

  Leukemia research 20120401

• Pro-inflammatory cytokines interleukin-1 beta, interleukin 6, and tumor necrosis factor-alpha alter the expression and function of ABCG2 in cervix and gastric cancer cells.

  Molecular and cellular biochemistry 20120401

• Role of structural factors of antitumour anthraquinone derivatives and analogues in the ability to undergo bioreductive activation by NADPH cytochrome P450 reductase: implications for increasing the activity against sensitive and multidrug-resistant leukaemia HL60 cells.

  Anti-cancer drugs 20120401

• Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20120401

• [2012: Update on diagnosis and treatment of multiple sclerosis].

  Deutsche medizinische Wochenschrift (1946) 20120401

• Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone.

  Neurology 20120320

• Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120315

• Phospho-specific flow: fixating on the target.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120315

• Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era.

  Leukemia & lymphoma 20120301

• Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma.

  Leukemia & lymphoma 20120301

• High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).

  Leukemia & lymphoma 20120301

• [Second line therapy for castration-resistant prostate cancer (CRPC)].

  Der Urologe. Ausg. A 20120301

• Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone.

  Pharmacological research 20120301

• Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia.

  American journal of hematology 20120301

• New induction and postinduction strategies in acute myeloid leukemia.

  Current opinion in hematology 20120301

• Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma).

  Annals of oncology : official journal of the European Society for Medical Oncology 20120301

• Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.

  Clinical genitourinary cancer 20120301

• ABCG2-overexpressing S1-M1-80 cell xenografts in nude mice keep original biochemistry and cell biological properties.

  Chinese journal of cancer 20120301

• Mitoxantrone as a prospective photosensitizer for photodynamic therapy of breast cancer.

  Photodiagnosis and photodynamic therapy 20120301

• [Current treatment of acute myeloid leukaemia in adults].

  Orvosi hetilap 20120219

• Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein.

  ACS chemical biology 20120217

• Mitoxantrone exerts both cytotoxic and immunoregulatory effects on activated microglial cells.

  Immunopharmacology and immunotoxicology 20120201

• A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120201

• Novel nanostructured lipid-dextran sulfate hybrid carriers overcome tumor multidrug resistance of mitoxantrone hydrochloride.

  Nanomedicine : nanotechnology, biology, and medicine 20120201

• Use of baculovirus BacMam vectors for expression of ABC drug transporters in mammalian cells.

  Drug metabolism and disposition: the biological fate of chemicals 20120201

• Magnetic drug targeting in a rhabdomyosarcoma rat model using magnetite-dextran composite nanoparticle-bound mitoxantrone and 0.6 tesla extracorporeal magnets - sarcoma treatment in progress.

  Journal of drug targeting 20120201

• Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane.

  Cancer chemotherapy and pharmacology 20120201

• Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone.

  Antiviral research 20120201

• Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis.

  APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 20120201

• A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.

  Anticancer research 20120201

• Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein.

  Journal of medicinal chemistry 20120126

• Mitoxantrone-loaded zeolite beta nanoparticles: preparation, physico-chemical characterization and biological evaluation.

  Journal of colloid and interface science 20120101

• Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.

  European journal of cancer (Oxford, England : 1990) 20120101

• Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20120101

• Long-term risk of leukaemia or cardiomyopathy after mitoxantrone therapy for multiple sclerosis.

  European neurology 20120101

• Effects of α-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport.

  PloS one 20120101

• [Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: the TROPIC study in France].

  Bulletin du cancer 20120101

• Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis.

  PloS one 20120101

• Subclinical anthracycline cardiotoxicity in patients with acute promyelocytic leukemia in long-term remission after the AIDA protocol.

  Congestive heart failure (Greenwich, Conn.) 20120101

• Evidence for mitoxantrone-induced block of inwardly rectifying K(+) channels expressed in the osteoclast precursor RAW 264.7 cells differentiated with lipopolysaccharide.

  Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 20120101

• Gene silencing of FANCF potentiates the sensitivity to mitoxantrone through activation of JNK and p38 signal pathways in breast cancer cells.

  PloS one 20120101

• Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.

  Health technology assessment (Winchester, England) 20120101

• Adenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-region.

  PloS one 20120101

• Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice.

  Science (New York, N.Y.) 20111216

• Hypoxia activated prodrugs of a 9-aza-anthrapyrazole derivative that has promising anticancer activity.

  Journal of medicinal chemistry 20111208

• FLANG salvage chemotherapy is an effective regimen that offers a safe bridge to transplantation for patients with relapsed or refractory acute myeloid leukemia.

  Medical oncology (Northwood, London, England) 20111201

• Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.

  Journal of neurology, neurosurgery, and psychiatry 20111201

• A population-based study of prostate cancer chemotherapy.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20111201

• Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.

  Clinical lymphoma, myeloma & leukemia 20111201

• In vitro and in vivo modulation of ABCG2 by functionalized aurones and structurally related analogs.

  Biochemical pharmacology 20111201

• Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients.

  Haematologica 20111201

• Cationic drug-derived nanoparticles for multifunctional delivery of anticancer siRNA.

  Biomaterials 20111201

• Autologous peripheral blood stem cell transplantation for acute myeloid leukemia.

  Blood 20111201

• A novel aza-anthrapyrazole blocks the progression of experimental autoimmune encephalomyelitis after the priming of autoimmunity.

  Clinical immunology (Orlando, Fla.) 20111201

• Multiple sclerosis- diagnosis, management and prognosis.

  Australian family physician 20111201

• Novel cytotoxic isolated from Jamaican Hyptis verticillata jacq induces apoptosis and overcomes multidrug resistance.

  Anticancer research 20111201

• [A systematic review of MA versus IA regimen for patients with acute myelogenous leukemia].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20111201

• PEGylated liposomes modified with LHRH analogs for tumor targeting.

  Journal of controlled release : official journal of the Controlled Release Society 20111130

• Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone.

  Neurology 20111122

• Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16).

  Blood 20111117

• In vitro synergism between LFA-1 targeting leukotoxin (Leukothera™) and standard chemotherapeutic agents in leukemia cells.

  Leukemia research 20111101

• Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial.

  British journal of haematology 20111101

• [Pregabalin and gabapentin in multiple sclerosis: clinical experiences and therapeutic implications].

  Der Nervenarzt 20111001

• Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.

  Annals of hematology 20110901

• Stability of cognitive functions under mitoxantrone therapy in patients with progressive multiple sclerosis: a pilot analysis.

  Clinical neurology and neurosurgery 20110901

• Intra-arterial mitoxantrone delivery in rabbits: an optical pharmacokinetic study.

  Neurosurgery 20110901

• MS Forum/MS Over the Past 17 Years.

  International MS journal 20110901

• ABCG2 is required to control the sonic hedgehog pathway in side population cells with stem-like properties.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20110901

• Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110901

• [A case of neuromyelitis optica with varicella zoster virus meningitis during mitoxantrone treatment].

  Rinsho shinkeigaku = Clinical neurology 20110901

• [Docetaxel-based chemotherapy for hormone-refractory prostate cancer in Japanese patients : experience in a single institute].

  Hinyokika kiyo. Acta urologica Japonica 20110901

• [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20110901

• Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and its analogues.

  Journal of medicinal chemistry 20110825

• A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis.

  Journal of the neurological sciences 20110815

• Mitoxantrone inhibits HIF-1α expression in a topoisomerase II-independent pathway.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110801

• Use of mitoxantrone in neuromyelitis optica.

  Archives of neurology 20110801

• What's up with down syndrome and leukemia-A lot!

  Pediatric blood & cancer 20110715

• Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study.

  Pediatric blood & cancer 20110715

• Mitoxantrone induced impediment of histone acetylation and structural flexibility of the protein.

  Cell biochemistry and biophysics 20110701

• Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy.

  Leukemia research 20110701

• Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20110701

• MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport.

  Biochemical pharmacology 20110701

• Glucocorticoid regulation of placental breast cancer resistance protein (Bcrp1) in the mouse.

  Reproductive sciences (Thousand Oaks, Calif.) 20110701

• Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110701

• GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC.

  Pharmacogenomics 20110701

• A pH-responsive cleavage route based on a metal-organic coordination bond.

  Chemistry (Weinheim an der Bergstrasse, Germany) 20110620

• Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy.

  Annals of hematology 20110601

• Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110601

• Tumor necrosis factor alpha induces stronger cytotoxicity in ABCG2-overexpressing resistant breast cancer cells compared with their drug-sensitive parental line.

  DNA and cell biology 20110601

• Multiple sclerosis: current treatment algorithms.

  Current opinion in neurology 20110601

• Increased incidence of central nervous system hemorrhages in patients with secondary acute promyelocytic leukemia after treatment of multiple sclerosis with mitoxantrone?

  Haematologica 20110601

• Use of diagnostic tests and procedures for disease-modifying therapy users and non-disease-modifying therapy users with multiple sclerosis.

  Expert review of neurotherapeutics 20110601

• Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110520

• Asymmetric enzymatic glycosylation of mitoxantrone.

  Organic letters 20110520

• Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy.

  Neurology 20110517

• Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2.

  Journal of medicinal chemistry 20110512

• 5,7-Dimethoxyflavone and multiple flavonoids in combination alter the ABCG2-mediated tissue distribution of mitoxantrone in mice.

  Pharmaceutical research 20110501

• [Specific palatal infiltration in B-cell chronic lymphocytic leukemia].

  Actas dermo-sifiliograficas 20110501

• Managing MS in a changing treatment landscape.

  Journal of neurology 20110501

• Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies.

  The American journal of managed care 20110501

• Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.

  Cancer research 20110415

• Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone.

  Acta neurologica Scandinavica 20110401

• Drug-induced Sweet's syndrome after mitoxantrone therapy in a patient with multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20110401

• Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica.

  Archives of neurology 20110401

• Five Chinese pediatric patients with leukemias possibly arising from immature natural killer cells: clinical features and courses.

  Pediatric hematology and oncology 20110401

• TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.

  Future oncology (London, England) 20110401

• Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.

  Blood 20110324

• Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes.

  Neurology 20110322

• Race and intensity of post-remission therapy in acute myeloid leukemia.

  Leukemia research 20110301

• Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110301

• Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.

  Cancer 20110301

• Salvaging AML with CLAG: novel option, or more of the same?

  Leukemia research 20110301

• Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens.

  Leukemia research 20110301

• A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma.

  Japanese journal of clinical oncology 20110301

• Investigating the enhancement of cisplatin cytotoxicity on 5637 cells by combination with mogoltacin.

  Toxicology in vitro : an international journal published in association with BIBRA 20110301

• Cabazitaxel: a new drug for metastatic prostate cancer.

  Asian journal of andrology 20110301

• A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.

  British journal of haematology 20110301

• Infusional mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for multiple myeloma.

  Cancer investigation 20110301

• Inhibition of unwinding and ATPase activities of pea MCM6 DNA helicase by actinomycin and nogalamycin.

  Plant signaling & behavior 20110301

• Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.

  Anti-cancer agents in medicinal chemistry 20110301

• Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy.

  Cancer chemotherapy and pharmacology 20110201

• Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines.

  Journal of cancer research and clinical oncology 20110201

• A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone.

  Cancer chemotherapy and pharmacology 20110201

• Spectral studies on the molecular interaction of anticancer drug mitoxantrone with CTAB micelles.

  Journal of pharmaceutical sciences 20110201

• Oxidative metabolism of the anti-cancer agent mitoxantrone by horseradish, lacto-and lignin peroxidase.

  Biochimie 20110201

• Molecular genetic basis for fluoroquinolone-induced retinal degeneration in cats.

  Pharmacogenetics and genomics 20110201

• Long-term follow-up of pediatric patients treated with mitoxantrone for multiple sclerosis.

  Neuropediatrics 20110201

• Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients.

  Blood 20110120

• Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells.

  Blood 20110113

• Cabazitaxel for castration-resistant prostate cancer.

  Lancet (London, England) 20110108

• Cabazitaxel for castration-resistant prostate cancer.

  Lancet (London, England) 20110108

• Liposomal imatinib-mitoxantrone combination: formulation development and therapeutic evaluation in an animal model of prostate cancer.

  The Prostate 20110101

• Mitoxantrone is expelled by the ABCG2 multidrug transporter directly from the plasma membrane.

  Biochimica et biophysica acta 20110101

• [Clinical, radiographic, prognostic and therapeutic aspects of demelinating disease with tumefactive demyelinating lesions].

  Revue neurologique 20110101

• Knockdown of caveolin-1 decreases activity of breast cancer resistance protein (BCRP/ABCG2) and increases chemotherapeutic sensitivity.

  Naunyn-Schmiedeberg's archives of pharmacology 20110101

• Interaction of mitoxantrone, as an anticancer drug, with chromatin proteins, core histones and H1, in solution.

  International journal of biological macromolecules 20110101

• Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia.

  British journal of haematology 20110101

• Tolerability and acceptance of prolonged low/delayed mitoxantrone regimens in patients with worsening multiple sclerosis.

  European neurology 20110101

• Biochemical and pharmacological effects of mitoxantrone and acetyl-L-carnitine in mice with a solid form of Ehrlich tumour.

  Chemotherapy 20110101

• Intra-arterial mitoxantrone/paclitaxel in angiosarcoma of the lower limb associated with chronic lymphedema (Stewart-Treves syndrome) in a patient with cervical cancer.

  European journal of dermatology : EJD 20110101

• Structure and function of ABCG2-rich extracellular vesicles mediating multidrug resistance.

  PloS one 20110101

• Current disease-modifying treatment of multiple sclerosis.

  The Mount Sinai journal of medicine, New York 20110101

• Molecular modeling study of interaction of anthracenedione class of drug mitoxantrone and its analogs with DNA tetrameric sequences.

  Advances in experimental medicine and biology 20110101

• Influence of anticancer therapy on oxidation phenotype and acetylation phenotype in patients with acute myeloblastic leukemia.

  Pharmacological reports : PR 20110101

• [Energetics of complex formation of the DNA hairpin structure d(GCGAAGC) with aromatic ligands].

  Biofizika 20110101

• Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma.

  BMC cancer 20110101

• [Severe skin reaction with mucous membrane inflammation during MINE chemotherapy].

  Annales de dermatologie et de venereologie 20110101

• The effect of ATM and ERK1/2 inhibition on mitoxantrone-induced cell death of leukaemic cells.

  Folia biologica 20110101

• Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells.

  PloS one 20110101

• Mitoxantrone in combination with a DNA-PK inhibitor: possible therapy of promyelocytic leukaemia resistant forms.

  Folia biologica 20110101

• Interaction of human multidrug and toxin extrusion 1 (MATE1) transporter with antineoplastic agents.

  Drug metabolism and drug interactions 20110101

• [Treatment of elderly patients with non-Hodgkin's lymphoma].

  Likars'ka sprava 20110101

• Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.

  Lancet (London, England) 20101211

• Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.

  Lancet (London, England) 20101211

• Mitoxantrone in first-relapse paediatric ALL: the ALL R3 trial.

  Lancet (London, England) 20101211

• Flower-like hierarchically nanostructured hydroxyapatite hollow spheres: facile preparation and application in anticancer drug cellular delivery.

  Chemistry, an Asian journal 20101203

• Effect of mitoxantrone on proliferation dynamics and cell-cycle progression.

  Bioscience reports 20101201

• Reduced dose-limiting toxicity of intraperitoneal mitoxantrone chemotherapy using cardiolipin-based anionic liposomes.

  Nanomedicine : nanotechnology, biology, and medicine 20101201

• Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.

  Clinical neurology and neurosurgery 20101201

• Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20101201

• A predictive ligand-based Bayesian model for human drug-induced liver injury.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• Receptor for activated C-kinase 1 regulates the cell surface expression and function of ATP binding cassette G2.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• Identification of specific inhibitors for a trypanosomatid RNA editing reaction.

  RNA (New York, N.Y.) 20101201

• [Mitoxantrone-related acute leukemia by multiple sclerosis. Case report and practical approach by unclear cytopenia].

  Der Nervenarzt 20101201

• A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse.

  Clinical lymphoma, myeloma & leukemia 20101201

• [Pharmacodynamics, pharmacokinetics and tissue distribution of liposomal mitoxantrone hydrochloride].

  Yao xue xue bao = Acta pharmaceutica Sinica 20101201

• The anti-oxidative role of ABCG2 in corneal epithelial cells.

  Investigative ophthalmology & visual science 20101101

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience.

  American journal of hematology 20101101

• Expression of noncoding vault RNA in human malignant cells and its importance in mitoxantrone resistance.

  Molecular cancer research : MCR 20101101

• New biomarkers probing depth of cell senescence assessed by laser scanning cytometry.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20101101

• TRAIL-expressing mesenchymal stem cells kill the putative cancer stem cell population.

  British journal of cancer 20101101

• Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.

  Cancer research 20101015

• On-line chemiluminescence determination of mitoxantrone by capillary electrophoresis.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20101015

• New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation.

  Journal of medicinal chemistry 20101014

• Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C.

  European journal of pharmacology 20101010

• Cabazitaxel in prostate cancer: stretching a string.

  Lancet (London, England) 20101002

• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

  Lancet (London, England) 20101002

• Mitoxantrone treatment in multiple sclerosis induces TH2-type cytokines.

  Acta neurologica Scandinavica 20101001

• Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.

  Breast cancer research and treatment 20101001

• Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts.

  Human gene therapy 20101001

• Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS).

  Cancer 20100915

• Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma.

  Medical oncology (Northwood, London, England) 20100901

• A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia.

  Medical oncology (Northwood, London, England) 20100901

• Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP.

  Medical oncology (Northwood, London, England) 20100901

• Off-line memory consolidation impairments in multiple sclerosis patients receiving high-dose corticosteroid treatment mirror consolidation impairments in depression.

  Psychoneuroendocrinology 20100901

• Determination of mitoxantrone in rat plasma by liquid chromatography-tandem mass spectrometry method: Application to a pharmacokinetic study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100815

• Beta-casein-based nanovehicles for oral delivery of chemotherapeutic drugs: drug-protein interactions and mitoxantrone loading capacity.

  Nanomedicine : nanotechnology, biology, and medicine 20100801

• Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20100801

• BCRP/ABCG2 confers anticancer drug resistance without covalent dimerization.

  Cancer science 20100801

• Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: association of DNA breaks with specific DNA motifs at PML and RARA loci.

  Genes, chromosomes & cancer 20100801

• Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.

  Assay and drug development technologies 20100801

• Preparation, characterization, and in vivo evaluation of mitoxantrone-loaded, folate-conjugated albumin nanoparticles.

  Archives of pharmacal research 20100801

• Rational design, synthesis, and DNA binding properties of novel sequence-selective peptidyl congeners of ametantrone.

  ChemMedChem 20100705

• Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

  Leukemia research 20100701

• Effects of single and multiple flavonoids on BCRP-mediated accumulation, cytotoxicity and transport of mitoxantrone in vitro.

  Pharmaceutical research 20100701

• Sequential flavopiridol, mitoxantrone and cytosine arabinoside for newly diagnosed poor risk acute myeloid leukemia. What to do next?

  Leukemia research 20100701

• Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.

  Cancer investigation 20100701

• Effects of the isoflavonoid biochanin A on the transport of mitoxantrone in vitro and in vivo.

  Biopharmaceutics & drug disposition 20100701

• Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis.

  Bone marrow transplantation 20100601

• Aggregation of spectrin and PKCtheta is an early hallmark of fludarabine/mitoxantrone/dexamethasone-induced apoptosis in Jurkat T and HL60 cells.

  Molecular and cellular biochemistry 20100601

• Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.

  The Journal of pharmacology and experimental therapeutics 20100601

• Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.

  Neurology 20100601

• Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant.

  Leukemia & lymphoma 20100601

• A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule.

  Hematology (Amsterdam, Netherlands) 20100601

• DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.

  Chemistry & biology 20100528

• Coupled spectral and electrochemical evaluation of the anticancer drug mitoxantrone-sodium dodecyl sulfate interaction.

  International journal of pharmaceutics 20100510

• Immunotherapy and multiple sclerosis: The devil is in the details.

  Neurology 20100504

• Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

  Neurology 20100504

• Pharmacokinetics and biliary excretion of mitoxantrone in rats.

  Journal of pharmaceutical sciences 20100501

• Genotoxic stress causes the accumulation of the splicing regulator Sam68 in nuclear foci of transcriptionally active chromatin.

  Nucleic acids research 20100501

• Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.

  Pediatric blood & cancer 20100501

• Adherence to recommended dosing and monitoring for mitoxantrone in patients with multiple sclerosis: a healthcare claims database study supplemented with medical records--the RETRO study.

  Pharmacoepidemiology and drug safety 20100501

• [Diagnosis and therapy in multiple sclerosis].

  Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS 20100501

• Inhibition of transcription factor assembly and structural stability on mitoxantrone binding with DNA.

  Bioscience reports 20100421

• Magnetic resonance evidence of cerebellar cortical pathology in multiple sclerosis.

  Journal of neurology, neurosurgery, and psychiatry 20100401

• KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone.

  Biological chemistry 20100401

• Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.

  Archives of neurology 20100401

• Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.

  Cancer 20100401

• (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20100401

• Rituximab plus dose-reduced cyclophosphamide, mitoxantrone, vincristine, and prednisolone are effective in elderly patients with diffuse large B-cell lymphoma of the thyroid.

  Thyroid : official journal of the American Thyroid Association 20100401

• Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer.

  American journal of clinical pathology 20100401

• Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines.

  Drug and chemical toxicology 20100401

• Multiple sclerosis: closing in on an oral treatment.

  Nature 20100318

• Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2.

  Biochemistry 20100316

• Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment.

  Neurology 20100316

• The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone.

  Structure (London, England : 1993) 20100314

• [Pharmacological treatment of multiple sclerosis].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20100311

• Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years.

  Leukemia research 20100301

• CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.

  The Prostate 20100301

• Intrathecal chemotherapy and meningeal relapses in myelomonocytic AML. A single institution experience.

  American journal of hematology 20100301

• Advantage of MIDAM protocol in treatment of elderly patients with refractory and relapsing acute myeloid leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100301

• Heart transplant in a childhood leukemia survivor: a case report.

  Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 20100301

• Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma.

  Veterinary and comparative oncology 20100301

• HPLC analysis of mitoxantrone in mouse plasma and tissues: application in a pharmacokinetic study.

  Journal of pharmaceutical and biomedical analysis 20100205

• Beta-casein nanovehicles for oral delivery of chemotherapeutic drugs.

  Nanomedicine : nanotechnology, biology, and medicine 20100201

• The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.

  European journal of cancer (Oxford, England : 1990) 20100201

• Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100201

• Multidrug resistance in breast cancer cells during epithelial-mesenchymal transition is modulated by breast cancer resistant protein.

  Chinese journal of cancer 20100201

• [Effect of physical exercise on the efficacy of mitoxantrone-loaded nanoparticles in treating early breast cancer].

  Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi 20100201

• Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia.

  Blood 20100114

• Mitoxantrone and cytotoxic drugs' mechanisms of action.

  Neurology 20100105

• Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.

  Cancer chemotherapy and pharmacology 20100101

• The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells.

  Phytotherapy research : PTR 20100101

• Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier.

  Cellular and molecular neurobiology 20100101

• Regulation of gene expression in brain tissues of rats repeatedly treated by the highly abused opioid agonist, oxycodone: microarray profiling and gene mapping analysis.

  Drug metabolism and disposition: the biological fate of chemicals 20100101

• VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: a multicenter experience.

  Archives of gerontology and geriatrics 20100101

• Inhibition of receptor tyrosine kinase signalling by small molecule agonist of T-cell protein tyrosine phosphatase.

  BMC cancer 20100101

• [Clinical study of sequential high-dose chemotherapy with in vivo rituximab-purged stem cell autografting for mantle cell lymphoma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20100101

• A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899.

  Journal of translational medicine 20100101

• [Patients older than 80 years with de novo acute myeloid leukemias without erythroblastic and/or megakaryocytic dysplasia achieve complete remission and longer survival after classical chemotherapy 3 + 7].

  Vnitrni lekarstvi 20100101

• [Evaluation of fludarabine-containing regimens versus immunochemotherapy for chronic lymphocytic leukemia].

  Terapevticheskii arkhiv 20100101

• Mitoxantrone loaded superparamagnetic nanoparticles for drug targeting: a versatile and sensitive method for quantification of drug enrichment in rabbit tissues using HPLC-UV.

  Journal of biomedicine & biotechnology 20100101

• TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters.

  BMC cancer 20100101

• Biclonal follicular lymphoma: histological, clinical and molecular characteristics.

  Pathology 20100101

• Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study.

  BMC clinical pharmacology 20100101

• Effects of chitosan coating on physical properties and pharmacokinetic behavior of mitoxantrone liposomes.

  International journal of nanomedicine 20100101

• Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes.

  International journal of nanomedicine 20100101

• Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells.

  PloS one 20100101

• Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients.

  Pediatric blood & cancer 20091215

• A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma.

  Nanomedicine : nanotechnology, biology, and medicine 20091201

• Restoring immune suppression in the multiple sclerosis brain.

  Progress in neurobiology 20091201

• Mitoxantrone-mediated apoptotic B16-F1 cells induce specific anti-tumor immune response.

  Cellular & molecular immunology 20091201

• Tumor-specific cytotoxicity and type of cell death induced by gefitinib in oral squamous cell carcinoma cell lines.

  Anticancer research 20091201

• Chemotherapy induces ATP release from tumor cells.

  Cell cycle (Georgetown, Tex.) 20091115

• Mitoxantrone analogues as ligands for a stem-loop structure of tau pre-mRNA.

  Journal of medicinal chemistry 20091112

• Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091110

• Additional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapy.

  Annals of hematology 20091101

• Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.

  Experimental hematology 20091101

• Multiple sclerosis. Part 2: ophthalmic issues in MS therapy.

  Current opinion in ophthalmology 20091101

• Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20091101

• Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin.

  Leukemia & lymphoma 20091101

• [Rescue treatments for multiple sclerosis].

  Rinsho shinkeigaku = Clinical neurology 20091101

• [Treatment of NMO].

  Rinsho shinkeigaku = Clinical neurology 20091101

• The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.

  Anticancer research 20091101

• Surface modification of mitoxantrone-loaded PLGA nanospheres with chitosan.

  Colloids and surfaces. B, Biointerfaces 20091015

• Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.

  Journal of medicinal chemistry 20091008

• Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma.

  Investigational new drugs 20091001

• Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20091001

• ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma.

  Journal of cancer research and clinical oncology 20091001

• B-type natriuretic peptide as a marker of subclinical heart injury during mitoxantrone therapy in MS patients--preliminary study.

  Clinical neurology and neurosurgery 20091001

• Incidence and outcome of patients with diffuse large B cell lymphoma with marrow involvement and preliminary experience of an adult acute lymphoblastic leukemia protocol (NEALL VI) in cyclophosphamide, doxorubicin, vincristine, and prednisolone--rituximab refractory patients.

  Leukemia & lymphoma 20091001

• Lack of ABCG2 expression and side population properties in human pluripotent stem cells.

  Stem cells (Dayton, Ohio) 20091001

• Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2.

  Molecular cancer therapeutics 20091001

• Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis.

  Therapeutic drug monitoring 20091001

• Treatment of multiple sclerosis: role of natalizumab.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20091001

• Mitoxantrone: benefits and risks in multiple sclerosis patients.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20091001

• Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment.

  Neurology 20090922

• Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090920

• Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs.

  The Prostate 20090915

• Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines.

  Cancer research 20090915

• Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.

  Cancer science 20090901

• [Patients with metastatic hormone-refractory prostate cancer. Second-line chemotherapy with mitoxantrone plus prednisone].

  Der Urologe. Ausg. A 20090901

• Dose-dependent melanonychia by mitoxantrone.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20090901

• ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.

  Brain : a journal of neurology 20090901

• Poly(ethylene glycol)-stabilized silver nanoparticles for bioanalytical applications of SERS spectroscopy.

  The Analyst 20090901

• Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20090901

• Bendamustine in chronic lymphocytic leukemia: the future is combination therapy.

  Leukemia & lymphoma 20090901

• Bendamustine/mitoxantrone/rituximab: a short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia.

  Leukemia & lymphoma 20090901

• Breast cancer resistance protein (BCRP/ABCG2): new inhibitors and QSAR studies by a 3D linear solvation energy approach.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20090812

• Continuous 24-h monitoring of electrocardiogram during anthracycline-based therapy in acute leukemia.

  Leukemia research 20090801

• Dynamic assessment of mitoxantrone resistance and modulation of multidrug resistance by valspodar (PSC833) in multidrug resistance human cancer cells.

  The Journal of pharmacology and experimental therapeutics 20090801

• Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?

  Multiple sclerosis (Houndmills, Basingstoke, England) 20090801

• [Successful induction of complete remission by gemtuzumab ozogamicin following chemotherapy in three patients with relapsed or refractory acute myeloid leukemia].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20090801

• Survival time of dogs with inflammatory mammary cancer treated with palliative therapy alone or palliative therapy plus chemotherapy.

  The Veterinary record 20090718

• Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.

  Bioorganic & medicinal chemistry 20090715

• Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay.

  Cancer research 20090715

• Shortened and intensified MJMA: an effective salvage therapy for relapsed and refractory lymphomas and a strong mobilizer of PBSCs.

  Bone marrow transplantation 20090701

• Idiopathic hyperammonemia (IHA) after dose-dense induction chemotherapy for acute myeloid leukemia: Case report and review of the literature.

  Leukemia research 20090701

• Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone.

  Leukemia & lymphoma 20090701

• Identification of a pancreatic stellate cell population with properties of progenitor cells: new role for stellate cells in the pancreas.

  The Biochemical journal 20090626

• Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters.

  Oncogene 20090618

• Cyclophosphamide therapy in pediatric multiple sclerosis.

  Neurology 20090616

• Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090610

• Doxorubicin and mitoxantrone drug eluting beads for the treatment of experimental peritoneal carcinomatosis in colorectal cancer.

  International journal of cancer 20090601

• What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?

  BJU international 20090601

• MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells.

  Molecular pharmacology 20090601

• Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).

  Pharmacoepidemiology and drug safety 20090601

• DNA damage response as a biomarker in treatment of leukemias.

  Cell cycle (Georgetown, Tex.) 20090601

• Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL).

  Bioconjugate chemistry 20090601

• Acquired acute myelogenous leukemia after therapy for acute promyelocytic leukemia with t(15;17): a case report and review of the literature.

  Puerto Rico health sciences journal 20090601

• A dual-fluorescence high-throughput cell line system for probing multidrug resistance.

  Assay and drug development technologies 20090601

• Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy.

  Chinese journal of integrative medicine 20090601

• Pentostatin treatment combinations in chronic lymphocytic leukemia.

  Clinical advances in hematology & oncology : H&O 20090601

• Isolation and identification of a new impurity in mitoxantrone hydrochloride.

  Die Pharmazie 20090601

• Regimen containing perarubicin for the treatment of newly diagnosed young patients with acute myeloid leukemia.

  Ai zheng = Aizheng = Chinese journal of cancer 20090601

• Structural basis for stabilization of the tau pre-mRNA splicing regulatory element by novantrone (mitoxantrone).

  Chemistry & biology 20090529

• Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090520

• Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells.

  Cancer gene therapy 20090501

• Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.

  Cancer 20090501

• Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies.

  Gynecologic oncology 20090501

• [Toxicity and efficacy of intermittent docetaxel chemotherapy for hormone refractory prostate cancer].

  Aktuelle Urologie 20090501

• [Stem cell therapy in multiple sclerosis: a clinical update].

  Zeitschrift fur Rheumatologie 20090501

• HIV and anal cancer outcomes: a single institution's experience.

  Diseases of the colon and rectum 20090501

• [Mitoxantrone for the treatment of patients with multiple sclerosis].

  Brain and nerve = Shinkei kenkyu no shinpo 20090501

• Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG.

  Blood 20090423

• Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.

  Leukemia research 20090401

• Assessment of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis: a tissue Doppler echocardiographic analysis.

  Echocardiography (Mount Kisco, N.Y.) 20090401

• Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?

  Multiple sclerosis (Houndmills, Basingstoke, England) 20090401

• The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.

  American journal of hematology 20090401

• Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon.

  American journal of hematology 20090401

• Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells.

  Cancer research 20090401

• CE can identify small molecules that selectively target soluble oligomers of amyloid beta protein and display antifibrillogenic activity.

  Electrophoresis 20090401

• Hematology: germinal center or nongerminal center DLBCL?

  Nature reviews. Clinical oncology 20090401

• [Bacillus cereus sepsis and subarachnoid hemorrhage following consolidation chemotherapy for acute myelogenous leukemia].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20090401

• Characterization of the inhibition of breast cancer resistance protein-mediated efflux of mitoxantrone by pharmaceutical excipients.

  International journal of pharmaceutics 20090331

• PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.

  Cell stem cell 20090306

• Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia.

  Leukemia 20090301

• Identification of a potential 'hotspot' DNA region in the RUNX1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation.

  Genes, chromosomes & cancer 20090301

• CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy.

  Leukemia 20090301

• Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial.

  Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 20090301

• Synthesis and cytotoxic properties of 4,11-bis[(aminoethyl)amino]anthra[2,3-b]thiophene-5,10-diones, novel analogues of antitumor anthracene-9,10-diones.

  Bioorganic & medicinal chemistry 20090301

• Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins.

  Molecular cancer therapeutics 20090301

• Biphenotypic acute leukemia treated with acute myeloid leukemia regimens: a case series.

  Journal of the National Medical Association 20090301

• How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?

  European journal of neurology 20090301

• Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study.

  European journal of neurology 20090301

• Drug rash with eosinophilia and systemic signs syndrome in a patient with multiple sclerosis.

  Clinical therapeutics 20090301

• Ni2+-mediated mitoxantrone encapsulation: improved efficacy of fast release formulation.

  International journal of pharmaceutics 20090223

• Phylogenetic conservation of the preapoptotic calreticulin exposure pathway from yeast to mammals.

  Cell cycle (Georgetown, Tex.) 20090215

• The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.

  Oncology reports 20090201

• The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone.

  Cancer research 20090201

• Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11.

  Thrombosis and haemostasis 20090201

• Concepts of induction and escalation therapy in multiple sclerosis.

  Journal of the neurological sciences 20090201

• Long-term experience with induction treatment regimens in multiple sclerosis.

  Journal of the neurological sciences 20090201

• Immunosuppression followed by immunomodulation.

  Journal of the neurological sciences 20090201

• Experimental evidence for killing the resistant cells and raising the efficacy and decreasing the toxicity of cytostatics and irradiation by mixtures of the agents of the passive antitumor defense system in the case of various tumor and normal cell lines in vitro.

  Cancer biotherapy & radiopharmaceuticals 20090201

• [Therapeutic effect and toxicity of compound vincristine liposome on breast cancer in nude mice].

  Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi 20090201

• Complex t(2;21;8)(p12;q22;q22): a variant t(8;21) in a patient with acute myeloid leukemia (AML-M2).

  Cancer genetics and cytogenetics 20090115

• The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.

  Prostate cancer and prostatic diseases 20090101

• A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia.

  Annals of hematology 20090101

• Value of information and value of implementation: application of an analytic framework to inform resource allocation decisions in metastatic hormone-refractory prostate cancer.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20090101

• Mitoxantrone does not restore the impaired suppressive function of natural regulatory T cells in patients suffering from multiple sclerosis. A longitudinal ex vivo and in vitro study.

  European neurology 20090101

• Higher liposomal membrane fluidity enhances the in vitro antitumor activity of folate-targeted liposomal mitoxantrone.

  Molecular pharmaceutics 20090101

• Anticancer drug-DNA interactions measured using a photoinduced electron-transfer mechanism based on luminescent quantum dots.

  Analytical chemistry 20090101

• Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells.

  Current eye research 20090101

• Successfully conservative treatment of large cervical choriocarcinoma with profuse vaginal bleeding.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20090101

• Studies on the binding affinity of anticancer drug mitoxantrone to chromatin, DNA and histone proteins.

  Journal of biomedical science 20090101

• Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients--analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO.

  BMC cancer 20090101

• Primary cutaneous large B-cell lymphoma, leg type, successfully treated with rituximab plus chemotherapy.

  European journal of dermatology : EJD 20090101

• A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy.

  PloS one 20090101

• Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting.

  Neurology India 20090101

• Invited commentary. Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting.

  Neurology India 20090101

• Invited commentary. Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting.

  Neurology India 20090101

• [Use of mitoxantrone in the treatment of multiple sclerosis].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20090101

• [Combined therapy of aggressive remitted multiple sclerosis with mitoxantrone in combination with copaxone].

  Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 20090101

• Mitroxantrone in multiple sclerosis.

  Neurology India 20090101

• Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence.

  Biochemistry 20081230

• Interaction of mitoxantrone with human serum albumin: spectroscopic and molecular modeling studies.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20081218

• A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer.

  BJU international 20081201

• High level functional expression of the ABCG2 multidrug transporter in undifferentiated human embryonic stem cells.

  Biochimica et biophysica acta 20081201

• [Use of mitoxantrone in early multiple sclerosis with malignant disease course. Observational study in 30 patients with clinical and MRI outcomes after one year].

  Revue neurologique 20081201

• Clustering of organ-specific autoimmunity: a case presentation of multiple sclerosis and connective tissue disorders.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20081201

• Treatment of invasive aspergillosis with nonmyeloablative allogeneic stem cell transplantation: the hunter becomes the hunted.

  American journal of hematology 20081201

• Repeated injection of pegylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase.

  The Journal of pharmacy and pharmacology 20081201

• Interactions of mitoxantrone with duplex and triplex DNA studied by electrospray ionization mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20081201

• Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial.

  Annals of surgery 20081201

• Early interferon beta treatment in multiple sclerosis: nursing care implications of the BENEFIT study.

  The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses 20081201

• New therapeutical approaches for non muscle invasive bladder cancer.

  Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 20081201

• Multiple sclerosis and the TNFRSF1A R92Q mutation: clinical characteristics of 21 cases.

  Neurology 20081125

• Dimethoxyaurones: Potent inhibitors of ABCG2 (breast cancer resistance protein).

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20081115

• Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081110

• The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.

  Clinical neurology and neurosurgery 20081101

• A preliminary study on MeO-PEG-PLGA-PEG-OMe nanoparticles as intravenous carriers.

  Journal of biomedical materials research. Part A 20081101

• Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20081101

• Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia.

  American journal of hematology 20081101

• Overexpression of cell surface cytokeratin 8 in multidrug-resistant MCF-7/MX cells enhances cell adhesion to the extracellular matrix.

  Neoplasia (New York, N.Y.) 20081101

• [A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081101

• Future research directions for the treatment of AML.

  Clinical advances in hematology & oncology : H&O 20081101

• Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells.

  Biochemical and biophysical research communications 20081024

• Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis.

  Blood 20081015

• Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis.

  Journal of the neurological sciences 20081015

• Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa.

  Annals of oncology : official journal of the European Society for Medical Oncology 20081001

• Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20081001

• Lipid composition and grafted PEG affect in vivo activity of liposomal mitoxantrone.

  International journal of pharmaceutics 20081001

• Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco-2 cells.

  International journal of cancer 20081001

• Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081001

• Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma.

  Japanese journal of clinical oncology 20081001

• Phosphorylation of p53 on Ser15 during cell cycle caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation.

  Cell cycle (Georgetown, Tex.) 20081001

• [Choice of early and escalation treatment options for multiple sclerosis].

  Der Nervenarzt 20081001

• Antipsychotic drugs inhibit the function of breast cancer resistance protein.

  Basic & clinical pharmacology & toxicology 20081001

• Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.

  Journal of neurology 20081001

• Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.

  Journal of neurology 20081001

• Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.

  Life sciences 20080926

• Modulation of breast cancer resistance protein (BCRP/ABCG2) by non-basic chalcone analogues.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20080902

• Lobeline, a piperidine alkaloid from Lobelia can reverse P-gp dependent multidrug resistance in tumor cells.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20080901

• The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death.

  Cell death and differentiation 20080901

• Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone).

  Annals of hematology 20080901

• Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer.

  Current opinion in supportive and palliative care 20080901

• Induction and add-on therapy with mitoxantrone and interferon beta in multiple sclerosis.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20080901

• Neuromyelitis optica: diagnosis, pathogenesis, and treatment.

  Current neurology and neuroscience reports 20080901

• Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel.

  Molecular cancer therapeutics 20080901

• Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters.

  Molecular cancer therapeutics 20080901

• Clinical investigations in aggressive non-Hodgkin lymphoma.

  Clinical advances in hematology & oncology : H&O 20080901

• Mitoxantrone-related acute leukemia in two MS patients.

  Acta neurologica Belgica 20080901

• Perspective on 'Chemotherapy for advanced prostate cancer: 25 years later': is it a mirage or an oasis?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080820

• A role for topoisomerase II alpha in the formation of radiation-induced chromatid breaks.

  British journal of cancer 20080819

• ERP57 membrane translocation dictates the immunogenicity of tumor cell death by controlling the membrane translocation of calreticulin.

  Journal of immunology (Baltimore, Md. : 1950) 20080815

• Copper ion-mediated liposomal encapsulation of mitoxantrone: the role of anions in drug loading, retention and release.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20080807

• The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.

  BJU international 20080805

• Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone.

  Neurology 20080805

• The effects of methylprednisolone and mitoxantrone on CCL5-induced migration of lymphocytes in multiple sclerosis.

  Acta neurologica Scandinavica 20080801

• Azathioprine in multiple sclerosis.

  Mini reviews in medicinal chemistry 20080801

• [Effects of mitoxantrone on the activity of human protein kinase CK2 holoenzyme].

  Ai zheng = Aizheng = Chinese journal of cancer 20080801

• Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia.

  Leukemia & lymphoma 20080801

• The postchemotherapy PSA surge syndrome.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080701

• Comment on: 'Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome'.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080701

• Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients' survival and quality of life.

  Anti-cancer drugs 20080701

• Frontline therapy for chronic lymphocytic leukemia: the dilemma continues.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080701

• Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties of novel indeno[2,1-c]quinolin-7-one and indeno[1,2-c]isoquinolin-5,11-dione derivatives.

  Journal of medicinal chemistry 20080626

• Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080601

• CNOP (mitoxantrone) chemotherapy is inferior to CHOP (doxorubicin) in the treatment of patients with aggressive non-Hodgkin lymphoma (meta-analysis).

  European journal of haematology 20080601

• Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer.

  Cancer treatment reviews 20080601

• Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20080601

• Kinetics of histone H2AX phosphorylation and Chk2 activation in A549 cells treated with topotecan and mitoxantrone in relation to the cell cycle phase.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20080601

• CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo.

  Oncology reports 20080601

• Effective multiple sclerosis management through improved patient assessment.

  The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses 20080601

• Pharmacologic management of multiple sclerosis.

  Urologic nursing 20080601

• Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20080601

• Assessment of DNA double-strand breaks and gammaH2AX induced by the topoisomerase II poisons etoposide and mitoxantrone.

  Mutation research 20080510

• Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080510

• Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.

  Journal of the National Cancer Institute 20080507

• Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.

  British journal of cancer 20080506

• Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?

  Journal of neuro-oncology 20080501

• A theoretical study on interactions between mitoxantrone as an anticancer drug and DNA: application in drug design.

  Chemical biology & drug design 20080501

• Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients.

  British journal of haematology 20080501

• Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080501

• Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis.

  Cancer genetics and cytogenetics 20080415

• Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatment.

  Journal of pharmaceutical sciences 20080401

• Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment.

  European journal of neurology 20080401

• Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).

  The Lancet. Oncology 20080401

• Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina.

  European journal of neurology 20080401

• Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20080401

• Difficulty of peripheral blood stem cell collection after multiple consolidation therapy in acute myeloid leukemia.

  Journal of clinical and experimental hematopathology : JCEH 20080401

• Biweekly docetaxel-containing chemotherapy may be the optimal schedule.

  Anti-cancer drugs 20080401

• Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080320

• Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.

  Journal of the neurological sciences 20080315

• Acute myelogenous leukemia associated with Ollier disease.

  Pediatric blood & cancer 20080301

• Treatment of multiple sclerosis with methylprednisolone and mitoxantrone modulates the expression of CXC chemokine receptors in PBMC.

  Journal of clinical immunology 20080301

• Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20080301

• Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype.

  Leukemia & lymphoma 20080301

• Mechanisms responsible for reduced cardiotoxicity of mitoxantrone compared to doxorubicin examined in isolated guinea-pig heart preparations.

  The Journal of veterinary medical science 20080301

• Severe bladder contracture leading to cystectomy after intravesical mitoxantrone chemotherapy.

  Anti-cancer drugs 20080301

• Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes.

  Cancer letters 20080218

• WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.

  Biochemical pharmacology 20080215

• A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.

  Cancer 20080215

• Spectroelectrochemistry of the redox activation of anti-cancer drug mitoxantrone.

  Bioelectrochemistry (Amsterdam, Netherlands) 20080201

• Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.

  European journal of haematology 20080201

• High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma.

  Haematologica 20080201

• Genotoxic stress-induced expression of p53 and apoptosis in leukemic clam hemocytes with cytoplasmically sequestered p53.

  Cancer research 20080201

• ABCG2 expression and side population abundance regulated by a transforming growth factor beta-directed epithelial-mesenchymal transition.

  Cancer research 20080201

• Pulmonary complications of novel antineoplastic agents for solid tumors.

  Chest 20080201

• Cyclic metabolites: chemical and biological considerations.

  Current drug metabolism 20080201

• Mitoxantrone: multiple sclerosis: too many serious adverse effects.

  Prescrire international 20080201

• Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080120

• Translocation (2;11)(q37;q23) in therapy-related myelodysplastic syndrome after treatment for acute promyelocytic leukemia.

  Cancer genetics and cytogenetics 20080115

• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080110

• Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.

  Journal of neurology, neurosurgery, and psychiatry 20080101

• Brain natriuretic peptide as a marker of cardiac toxicity in patients with multiple sclerosis treated with mitoxantrone.

  Journal of neurology 20080101

• Long-term outcome of adjuvant chemotherapy cyclophosphamide, mitoxantrone, and fluorouracil in women with breast cancer.

  Acta oncologica (Stockholm, Sweden) 20080101

• Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080101

• Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: promising results in marginal zone lymphoma.

  Leukemia & lymphoma 20080101

• Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.

  Current topics in microbiology and immunology 20080101

• [Cognitive impact of mitoxantrone and methylprednisolone in multiple sclerosis: an open label study].

  Revue neurologique 20080101

• Successful rescue of an apocrine gland carcinoma metastatic to the cervical lymph nodes by mitoxantrone coupled with trains of permeabilizing electrical pulses (electrochemotherapy).

  In vivo (Athens, Greece) 20080101

• Localized small-bowel infarction caused by Aspergillus during chemotherapy for acute myeloid leukemia: report of a case.

  Surgery today 20080101

• Current status of cytotoxic chemotherapy in patients with metastatic prostate cancer.

  Urologic oncology 20080101

• Prognostic impact of combined fludarabine, treosulfan and mitoxantrone resistance profile in childhood acute myeloid leukemia.

  Anticancer research 20080101

• Substantial activity of mitoxantrone and paclitaxel in a heavily pre-treated metastatic bladder cancer patient.

  The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society 20080101

• Interactions between antitumor drugs and vault RNA.

  Nucleic acids symposium series (2004) 20080101

• Increased multidrug resistance-associated protein activity in mononuclear cells of patients with systemic lupus erythematosus.

  Clinical and experimental rheumatology 20080101

• Use of fludarabine-containing chemotherapeutic regimen results in durable complete remission of subcutaneous panniculitis-like T-cell lymphoma.

  American journal of clinical dermatology 20080101

• High-dose chemotherapy with autologous stem cell rescue in stage IIIB inflammatory breast cancer.

  Anticancer research 20080101

• Quantitative online detection of low-concentrated drugs via a SERS microfluidic system.

  Chemphyschem : a European journal of chemical physics and physical chemistry 20071221

• Phase II study of sequential chemotherapy with docetaxel-estramustine followed by mitoxantrone-prednisone in patients with advanced hormone-refractory prostate cancer.

  British journal of cancer 20071217

• Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071210

• Effect of excipients on breast cancer resistance protein substrate uptake activity.

  Journal of controlled release : official journal of the Controlled Release Society 20071204

• Two cases of isolated symptomatic myocarditis induced by all-trans retinoic acid (ATRA).

  Annals of hematology 20071201

• Aplidin synergizes with cytosine arabinoside: functional relevance of mitochondria in Aplidin-induced cytotoxicity.

  Leukemia 20071201

• In vitro and in vivo pharmacological profile of UFP-512, a novel selective delta-opioid receptor agonist; correlations between desensitization and tolerance.

  British journal of pharmacology 20071201

• Integration of 18O labeling and solution isoelectric focusing in a shotgun analysis of mitochondrial proteins.

  Journal of proteome research 20071201

• Therapeutic effect of anthracene-based anticancer agent ethonafide in an animal model of multiple sclerosis.

  Journal of immunology (Baltimore, Md. : 1950) 20071201

• Targeting of Sp1 transcription factor: a novel therapeutic approach for keloids, an in vitro analysis.

  Experimental dermatology 20071201

• The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2.

  Molecular cancer therapeutics 20071201

• Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter.

  Molecular cancer therapeutics 20071201

• [Nursing care of patients with basic multiple sclerosis therapy: preventing relapses].

  Pflege Zeitschrift 20071201

• Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades.

  Growth factors (Chur, Switzerland) 20071201

• Synthesis and biological evaluation of novel cytotoxic azanaphthoquinone annelated pyrrolo oximes.

  Bioorganic & medicinal chemistry letters 20071115

• Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.

  Cancer research 20071115

• The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids.

  British journal of pharmacology 20071101

• Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis.

  Current medical research and opinion 20071101

• Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML.

  Leukemia & lymphoma 20071101

• Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up.

  European journal of neurology 20071101

• A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071101

• VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly.

  Leukemia & lymphoma 20071101

• [A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute].

  Gan to kagaku ryoho. Cancer & chemotherapy 20071101

• [MALT (mucosa-associated lymphoid tissue) lymphoma of the lacrimal gland].

  Journal francais d'ophtalmologie 20071101

• Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG).

  International journal of hematology 20071101

• Neoadjuvant chemotherapy in locally advanced primary breast cancers: the Nottingham experience.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20071001

• Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia.

  Leukemia 20071001

• A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2).

  The Journal of pharmacology and experimental therapeutics 20071001

• Patterns of care study of breast-conserving therapy in Japan: comparison of the treatment process between 1995 1997 and 1999 2001 surveys.

  Japanese journal of clinical oncology 20071001

• Malignant pericardial effusion secondary to ovarian adenocarcinoma: a case report.

  The Journal of reproductive medicine 20071001

• Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer.

  Journal of chemotherapy (Florence, Italy) 20071001

• Reversal of BCRP-mediated multidrug resistance by stable expression of small interfering RNAs.

  Journal of cellular biochemistry 20070901

• Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20070901

• Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma: Japan Clinical Oncology Group Study 9004.

  Cancer science 20070901

• [Recent advances in the pathogenesis and immunotherapy of multiple sclerosis].

  Der Nervenarzt 20070901

• Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070901

• Roscovitine in B-chronic lymphocytic leukemia cells: high apoptosis-inducing efficacy and synergism with alemtuzumab independent of the patients' pretreatment status.

  Haematologica 20070901

• Non-Hodgkin's lymphoma in the elderly. Part 2: treatment of diffuse aggressive lymphomas.

  Oncology (Williston Park, N.Y.) 20070901

• [A case of recurrent renal cell carcinoma which recurred after fourth surgical resection and survived for about 2 years by medroxyporgesterone acetate administration].

  Hinyokika kiyo. Acta urologica Japonica 20070901

• [A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20070901

• Photochemical internalisation of chemotherapy potentiates killing of multidrug-resistant breast and bladder cancer cells.

  British journal of cancer 20070820

• Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis.

  Journal of the neurological sciences 20070815

• Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.

  Pediatric blood & cancer 20070801

• Re: Fabio Calabrò and Cora N. Sternberg. Current indications for chemotherapy in prostate cancer patients. Eur urol 2007;51:17-26.

  European urology 20070801

• Paraneoplastic Sweet's syndrome and the pathergy phenomenon.

  Annals of hematology 20070801

• Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis.

  Annals of surgical oncology 20070801

• On the origin of the decrease in stability of the DNA hairpin d(GCGAAGC) on complexation with aromatic drugs.

  Biophysical chemistry 20070801

• Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).

  Leukemia 20070801

• Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

  Cancer 20070801

• Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070801

• Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy.

  The Journal of dermatology 20070801

• Hyperforin inhibits P-gp and BCRP activities in chronic lymphocytic leukaemia cells and myeloid cells.

  Leukemia & lymphoma 20070801

• Leukaemia due to mitoxantrone.

  Prescrire international 20070801

• Requirement of Apaf-1 for mitochondrial events and the cleavage or activation of all procaspases during genotoxic stress-induced apoptosis.

  The Biochemical journal 20070701

• Expression of the ATP-binding cassette membrane transporter, ABCG2, in human and rodent brain microvessel endothelial and glial cell culture systems.

  Pharmaceutical research 20070701

• The effect of short-term intensive chemotherapy on reactivation of tuberculosis.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070701

• High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).

  Leukemia & lymphoma 20070701

• Salvage immuno-chemotherapy with a combination of rituximab, high-dose cytarabine, mitoxantrone and dexamethasone for patients with primary CNS lymphoma: a preliminary study.

  Leukemia & lymphoma 20070701

• [Mitoxantrone for the treatment of Japanese patients with multiple sclerosis].

  Rinsho shinkeigaku = Clinical neurology 20070701

• [Prostate cancer and chemotherapy].

  Bulletin du cancer 20070701

• Therapy-related acute nonlymphoblastic leukemia following mitoxantrone therapy in a patient with multiple sclerosis.

  Journal of the Mississippi State Medical Association 20070701

• C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.

  Biochemical pharmacology 20070630

• Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs.

  Cancer research 20070615

• Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone.

  Investigational new drugs 20070601

• Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells.

  The Journal of pharmacology and experimental therapeutics 20070601

• Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience.

  Annals of hematology 20070601

• The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors.

  Leukemia 20070601

• Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis.

  Expert opinion on pharmacotherapy 20070601

• Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20070601

• Multiple sclerosis in Pakistan.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20070601

• Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.

  Current medical research and opinion 20070601

• Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.

  Leukemia & lymphoma 20070601

• Energy transfer to analyse membrane-integrated mitoxantrone in BCRP-overexpressed cells.

  Journal of photochemistry and photobiology. B, Biology 20070525

• [Advances in the treatment of multiple sclerosis?].

  MMW Fortschritte der Medizin 20070521

• Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070520

• Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis.

  Journal of immunology (Baltimore, Md. : 1950) 20070515

• Mitoxantrone for multiple sclerosis causing acute lymphoblastic leukemia.

  Neurology 20070508

• The first case of mitoxantrone exposure in early pregnancy.

  Neurotoxicology 20070501

• Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells.

  International journal of cancer 20070501

• Differential subcellular distribution of mitoxantrone in relation to chemosensitization in two human breast cancer cell lines.

  Drug metabolism and disposition: the biological fate of chemicals 20070501

• Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines.

  Leukemia 20070501

• Evaluation of relative DNA binding affinities of anthrapyrazoles by electrospray ionization mass spectrometry.

  Journal of mass spectrometry : JMS 20070501

• Influence of cladribine alone and in combination with cyclophosphamide or cyclophosphamide and mitoxantrone on bone marrow angiogenesis in chronic lymphocytic leukemia.

  Leukemia & lymphoma 20070501

• Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.

  Haematologica 20070501

• Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells.

  Molecular cancer therapeutics 20070501

• The first 2 years of clinical experience with peripheral blood stem cell transplantation for various hematological malignancies: results from a single Baskent University Center.

  Transplantation proceedings 20070501

• A novel substrate mimetic inhibitor of PKB/Akt inhibits prostate cancer tumor growth in mice by blocking the PKB pathway.

  Biochemistry 20070424

• Acridone derivatives: design, synthesis, and inhibition of breast cancer resistance protein ABCG2.

  Bioorganic & medicinal chemistry 20070415

• Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.

  Cancer 20070415

• Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line.

  Cancer research 20070415

• Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors.

  Drug metabolism and disposition: the biological fate of chemicals 20070401

• MEK-ERK is involved in SUMO-1 foci formation on apoptosis.

  Cancer science 20070401

• QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.

  Anti-cancer drugs 20070401

• [Preparation of liposome entrapped vincristine sulfate and mitoxantrone chlorhydric acid].

  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20070401

• Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.

  Pediatric blood & cancer 20070301

• Evaluation of the myocardial performance index for early detection of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.

  European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology 20070301

• Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.

  Leukemia 20070301

• Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.

  Leukemia 20070301

• Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.

  Leukemia 20070301

• Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation.

  Haematologica 20070301

• [Hodgkin lymphoma in Chile: experience of the national adult cancer program].

  Revista medica de Chile 20070301

• Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

  Blood 20070215

• Proteomic analysis of prodigiosin-induced apoptosis in a breast cancer mitoxantrone-resistant (MCF-7 MR) cell line.

  Investigational new drugs 20070201

• Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.

  Molecular and cellular biochemistry 20070201

• Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer.

  Anti-cancer drugs 20070201

• Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis.

  Journal of neurology, neurosurgery, and psychiatry 20070201

• Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070201

• 3-methylcrotonyl-CoA carboxylase deficiency and severe multiple sclerosis.

  Pediatric neurology 20070201

• [Mandibular chloroma].

  Revue de stomatologie et de chirurgie maxillo-faciale 20070201

• Induction of ATM activation, histone H2AX phosphorylation and apoptosis by etoposide: relation to cell cycle phase.

  Cell cycle (Georgetown, Tex.) 20070201

• [A case of multiple lung metastases of hepatocellular carcinoma after resection of liver and tumor thrombi in the inferior vena cava responding to chemotherapy using 5-FU, mitoxantrone and CDDP].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070201

• [A case of malignant meningioma treated by individual adjuvant chemotherapy based on the mRNA expression of drug-resistance gene].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070201

• Use of rituximab in patients with follicular lymphoma.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20070201

• Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070120

• Cutaneous recall phenomenon at the site of previous doxorubicin extravasation after second-line chemotherapy.

  Journal of the National Cancer Institute 20070117

• Bioreductive activation of mitoxantrone by NADPH cytochrome P450 reductase. Implications for increasing its ability to inhibit the growth of sensitive and multidrug resistant leukaemia HL60 cells.

  Cancer letters 20070108

• Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties.

  Cancer chemotherapy and pharmacology 20070101

• Current indications for chemotherapy in prostate cancer patients.

  European urology 20070101

• The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models.

  Molecular pharmacology 20070101

• Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma.

  Cancer science 20070101

• Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070101

• Late relapses in acute promyelocytic leukaemia.

  Acta haematologica 20070101

• Epithelial-mesenchymal interactions in keloid pathogenesis modulate vascular endothelial growth factor expression and secretion.

  The Journal of pathology 20070101

• Mitoxantrone reduced disability in Iranian patients with multiple sclerosis.

  Archives of Iranian medicine 20070101

• [Concurrent chemo-radiotherapy for localized refractory non-Hodgkin's lymphoma--report of two cases].

  Gan to kagaku ryoho. Cancer & chemotherapy 20070101

• Three-dimensional cellular spheroid formation provides human prostate tumor cells with tissue-like features.

  Anticancer research 20070101

• Mitoxantrone permeability in MDCKII cells is influenced by active influx transport.

  Molecular pharmaceutics 20070101

• Immunomodulatory treatment of multiple sclerosis in Norway.

  Acta neurologica Scandinavica. Supplementum 20070101

• Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer.

  Cancer journal (Sudbury, Mass.) 20070101

• N-glycan alterations are associated with drug resistance in human hepatocellular carcinoma.

  Molecular cancer 20070101

• [Optimization of treatment options through a multidisciplinary approach for advanced hormone refractory prostate carcinoma].

  Tumori 20070101

• Curcumin as chemosensitizer.

  Advances in experimental medicine and biology 20070101

• Flexible low-intensity combination chemotherapy for elderly patients with acute myeloid leukaemia: a multicentre, phase II study.

  Drugs & aging 20070101

• Proteomic analysis to dissect mitoxantrone resistance-associated proteins in a squamous lung carcinoma.

  Anticancer research 20070101

• Resistance-associated signatures in breast cancer.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20070101

• Optical method for real-time monitoring of drug concentrations facilitates the development of novel methods for drug delivery to brain tissue.

  Journal of biomedical optics 20070101

• Combined low-dose cytarabine, melphalan and mitoxantrone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.

  Anticancer research 20070101

• [The results of a multicenter randomized trial on the treatment of acute myeloid leukemia of adults].

  Terapevticheskii arkhiv 20070101

• Therapeutic options for hormone-refractory prostate cancer in 2007.

  Urologic oncology 20070101

• Feasibility and efficacy of chemotherapy with gemcitabine mono and with paclitaxel/mitoxantron in gynaecological cancers.

  European journal of gynaecological oncology 20070101

• Sensitization against anticancer drugs by transfection with UBE2I variant gene into ras-NIH3H3 mouse fibroblasts.

  Anticancer research 20070101

• Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.

  Urologia internationalis 20070101

• Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs--pharmacy and medical benefit spending from 2004 through 2007.

  Journal of managed care pharmacy : JMCP 20070101

• Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines.

  Oncology research 20070101

• Survival benefit with GM-CSF use after high-dose chemotherapy in high-risk breast cancer.

  Tumori 20070101

• Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).

  Blood 20061215

• Comment on electron transfer vs differential decay in irradiated DNA.

  The journal of physical chemistry. B 20061214

• Evaluation of the antineoplastic activity of mitoxantrone-L-carnitine combination therapy on an experimental solid form of ehrlich tumour in mice.

  Pharmacological research 20061201

• Two new cases of acute promyelocytic leukemia following mitoxantrone treatment in patients with multiple sclerosis.

  Leukemia 20061201

• In vitro sensitivity of B-cell chronic lymphocytic leukemia to cladribine and its combinations with mafosfamide and/or mitoxantrone.

  Oncology reports 20061201

• [Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].

  Der Nervenarzt 20061201

• Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20061201

• Long-term follow-up of autologous peripheral blood stem cell transplantation in the treatment of a patient with acute panmyelosis with myelofibrosis.

  Haematologica 20061201

• [Superior sagittal sinus thrombosis during remission induction therapy for acute lymphoblastic leukemia].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20061201

• Treatment of malignant gliomas with mitoxantrone-loaded poly (lactide-co-glycolide) microspheres.

  Neurosurgery 20061201

• [Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice].

  Yao xue xue bao = Acta pharmaceutica Sinica 20061201

• [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].

  Ideggyogyaszati szemle 20061120

• Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter.

  British journal of pharmacology 20061101

• Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells.

  International journal of oncology 20061101

• Microtransponders, the miniature RFID electronic chips, as platforms for cell growth in cytotoxicity assays.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20061101

• Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis.

  Archives of neurology 20061101

• [Preparation of mitoxantrone liposomes and study on its in vivo distribution in rats after transdermal delivery].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20061101

• Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).

  Annals of hematology 20061001

• Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20061001

• Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial.

  Leukemia 20061001

• Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060920

• Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.

  Cancer chemotherapy and pharmacology 20060901

• Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma.

  Cancer science 20060901

• Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.

  Cancer 20060901

• Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery: in regards to Toledano et al. (Int J Radiat Oncol Biol Phys 2006;65:324-332).

  International journal of radiation oncology, biology, physics 20060901

• Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.

  Journal of neurology 20060901

• Fertility in patients with multiple sclerosis: current knowledge and future perspectives.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20060901

• Anti-cancer activities of 1,4-naphthoquinones: a QSAR study.

  Anti-cancer agents in medicinal chemistry 20060901

• A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer.

  British journal of cancer 20060821

• The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders.

  Cancer 20060815

• Postirradiation electron transfer vs differential radical decay in X-irradiated DNA and its mixtures with additives. Electron spin resonance spectroscopy in LiBr glass at low temperatures.

  The journal of physical chemistry. B 20060803

• Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study.

  Journal of neurology 20060801

• Upregulation of secretory connective tissue growth factor (CTGF) in keratinocyte-fibroblast coculture contributes to keloid pathogenesis.

  Journal of cellular physiology 20060801

• Activation of ATM and histone H2AX phosphorylation induced by mitoxantrone but not by topotecan is prevented by the antioxidant N-acetyl-L-cysteine.

  Cancer biology & therapy 20060801

• Purification of breast cancer resistance protein ABCG2 and role of arginine-482.

  Cellular and molecular life sciences : CMLS 20060801

• Combined effect of low-power laser irradiation and anthraquinone anticancer drug aclarubicin on survival of immortalized cells: Comparison with mitoxantrone.

  Cell biology international 20060801

• Surgifoam and mitoxantrone in the glioblastoma multiforme postresection cavity: the first step of locoregional chemotherapy through an ad hoc-placed catheter: technical note.

  Neurosurgery 20060801

• [Effect of several anti-tumor drugs on apoptosis induction in Jurkat cell line].

  Zhongguo shi yan xue ye xue za zhi 20060801

• Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin.

  Molecular cancer therapeutics 20060801

• High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.

  Leukemia & lymphoma 20060801

• Important differences between topoisomerase-I and -II targeting agents.

  Cancer biology & therapy 20060801

• The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2.

  Biochemistry 20060725

• Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression.

  Blood 20060715

• Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2).

  Blood 20060715

• In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.

  International journal of cancer 20060715

• Metabolites of ginsenosides as novel BCRP inhibitors.

  Biochemical and biophysical research communications 20060714

• Digitoxin, at concentrations commonly found in the plasma of cardiac patients, antagonizes etoposide and idarubicin activity in K562 leukemia cells.

  Leukemia research 20060701

• Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport.

  Molecular pharmacology 20060701

• Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).

  Archives of neurology 20060701

• Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060620

• Gene expression profiles of two accelerations in a CML patient.

  Leukemia research 20060601

• Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study.

  International journal of radiation oncology, biology, physics 20060601

• Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.

  Cancer 20060601

• CD24 Ala/Val polymorphism and multiple sclerosis.

  Journal of neuroimmunology 20060601

• [Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conservative surgery enhances late toxicities].

  Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 20060601

• Immunological studies of mitoxantrone in primary progressive MS.

  Journal of neuroimmunology 20060601

• Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone.

  American journal of hematology 20060601

• Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.

  BJU international 20060601

• Preparation of DHAQ-loaded mPEG-PLGA-mPEG nanoparticles and evaluation of drug release behaviors in vitro/in vivo.

  Journal of materials science. Materials in medicine 20060601

• Optimization of preparation of DHAQ-loaded PEG-PLGA-PEG nonaparticles using central composite design.

  Journal of materials science. Materials in medicine 20060601

• Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060601

• Multidrug resistance and stem cells in acute myeloid leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060601

• ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060601

• Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20060601

• Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes.

  Urology 20060601

• Current chemotherapeutic approaches for androgen-independent prostate cancer.

  Current opinion in investigational drugs (London, England : 2000) 20060601

• The structure of PknB in complex with mitoxantrone, an ATP-competitive inhibitor, suggests a mode of protein kinase regulation in mycobacteria.

  FEBS letters 20060529

• Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.

  Neurology 20060509

• Regulation of BCRP/ABCG2 expression by progesterone and 17beta-estradiol in human placental BeWo cells.

  American journal of physiology. Endocrinology and metabolism 20060501

• Targeting cancer cells: magnetic nanoparticles as drug carriers.

  European biophysics journal : EBJ 20060501

• Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20060501

• Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1).

  Lung cancer (Amsterdam, Netherlands) 20060501

• Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models.

  The Journal of urology 20060501

• The significance of minimal residual disease kinetics in adults with newly diagnosed PML-RARalpha-positive acute promyelocytic leukemia: results of a prospective trial.

  Haematologica 20060501

• Changing perspectives of the role of chemotherapy in advanced prostate cancer.

  The Urologic clinics of North America 20060501

• [Development of acute type, CD 8 positive adult T-cell leukemia in a carrier of hepatitis B virus--possible therapeutic effect of lamivudine combined with chemotherapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060501

• [Preparation and characterization of transfersomes of three drugs in vitro].

  Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 20060501

• Treatment of relapsed acute myeloid leukaemia.

  Reviews on recent clinical trials 20060501

• Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

  Journal of the National Cancer Institute 20060419

• Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux.

  Molecular pharmacology 20060401

• Circulating chromogranin a and hormone refractory prostate cancer chemotherapy.

  The Journal of urology 20060401

• Chemotherapy for high-risk localized prostate cancer.

  BJU international 20060401

• Synthesis and antitumor evaluation of symmetrical 1,5-diamidoanthraquinone derivatives as compared to their disubstituted homologues.

  Chemical & pharmaceutical bulletin 20060401

• [Alteration of expression of survivin in HL-60 cells treated with chemotherapeutic drugs].

  Zhongguo shi yan xue ye xue za zhi 20060401

• Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3sigma.

  Molecular cancer therapeutics 20060401

• Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.

  Archives of Iranian medicine 20060401

• [A case of secondary malignant lymphoma of the urinary bladder].

  Hinyokika kiyo. Acta urologica Japonica 20060401

• Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease.

  Leukemia & lymphoma 20060401

• The role of post-remission chemotherapy for older patients with acute myelogenous leukemia.

  Leukemia & lymphoma 20060401

• Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group.

  Leukemia & lymphoma 20060401

• Mitoxantrone plus gemcitabine in pretreated patients with metastatic breast cancer.

  Journal of chemotherapy (Florence, Italy) 20060401

• Management of worsening multiple sclerosis with mitoxantrone: a review.

  Clinical therapeutics 20060401

• Treatment of acute myeloid leukemia in older adults: time to reflect?

  Leukemia & lymphoma 20060401

• Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration.

  British journal of cancer 20060327

• A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma.

  British journal of cancer 20060327

• PS exposure increases the susceptibility of cells to fusion with DOTAP liposomes.

  Chemico-biological interactions 20060325

• A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.

  International journal of radiation oncology, biology, physics 20060315

• Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis.

  Cancer research 20060315

• Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institution.

  Leukemia & lymphoma 20060301

• Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.

  British journal of haematology 20060301

• First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?

  Cancer 20060301

• Positron emission tomography--positive distal femur following fludarabine, dexamethasone and mitoxantrone chemotherapy.

  British journal of haematology 20060301

• A high-throughput cell-based assay for inhibitors of ABCG2 activity.

  Journal of biomolecular screening 20060301

• The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks?

  Expert opinion on drug safety 20060301

• Mitoxantrone, carboplatin, cytosine arabinoside, and methylprednisolone followed by autologous peripheral blood stem cell transplantation: a salvage regimen for patients with refractory or recurrent non-Hodgkin lymphoma.

  Cancer 20060215

• Modulation of p-glycoprotein and breast cancer resistance protein by some prescribed corticosteroids.

  European journal of pharmacology 20060215

• Evaluation of carbon dioxide laser ablation combined with mitoxantrone and piroxicam treatment in dogs with transitional cell carcinoma.

  Journal of the American Veterinary Medical Association 20060215

• Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells.

  Cancer research 20060215

• Relationship between therapeutic efficacy of arterial infusion chemotherapy and expression of P-glycoprotein and p53 protein in advanced hepatocellular carcinoma.

  World journal of gastroenterology 20060214

• Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia.

  Leukemia research 20060201

• Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer.

  Urology 20060201

• [Mitoxantrone in the treatment of multiple sclerosis: risks and benefits].

  Revue neurologique 20060201

• [Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients].

  Revue neurologique 20060201

• [Acute leukaemia in two multiple sclerosis patients treated with mitoxantrone].

  Revue neurologique 20060201

• [Investigation on the properties of mitoxantrone-insulin conjugates lyophilized powder].

  Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi 20060201

• Doxetaxel: new indication. Prostate cancer: a few more weeks.

  Prescrire international 20060201

• [Acute airway obstruction during chemotherapy-induced agranulocytosis with fever].

  Revue de pneumologie clinique 20060201

• Mitoxantrone-loaded BSA nanospheres and chitosan nanospheres for local injection against breast cancer and its lymph node metastases. II: Tissue distribution and pharmacodynamics.

  International journal of pharmaceutics 20060113

• Mitoxantrone-loaded BSA nanospheres and chitosan nanospheres for local injection against breast cancer and its lymph node metastases. I: Formulation and in vitro characterization.

  International journal of pharmaceutics 20060113

• Therapeutic role of mitoxantrone in multiple sclerosis.

  Pharmacology & therapeutics 20060101

• Non-Hodgkin disease in beta-thalassemia major.

  American journal of hematology 20060101

• Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane.

  Annals of neurology 20060101

• Mitoxantrone in multiple sclerosis.

  Advances in neurology 20060101

• Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease.

  Cleveland Clinic journal of medicine 20060101

• Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.

  Clinical and experimental pharmacology & physiology 20060101

• Transport of glyburide by placental ABC transporters: implications in fetal drug exposure.

  Placenta 20060101

• [Tumor cell targetability of folate receptor-mediated mitoxantrone albumin nanoparticles].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20060101

• Expression of ABC transporters in human hepatocyte carcinoma cells with cross-resistance to epirubicin and mitoxantrone.

  Anticancer research 20060101

• Differential regulation of NF-kappaB activation and function by topoisomerase II inhibitors.

  BMC cancer 20060101

• Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer.

  Urologic oncology 20060101

• Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments.

  BMC cancer 20060101

• Skin involvement in Hodgkin's disease.

  Cancer investigation 20060101

• Mitoxantrone changes spectrin-aminophospholipid interactions.

  Molecular membrane biology 20060101

• The changing pattern of management for hormone-refractory, metastatic prostate cancer.

  Prostate cancer and prostatic diseases 20060101

• Gemcitabine plus mitoxantrone and prednisone in the palliative treatment of hormone-resistant prostate cancer (HRPC): A phase II study (GOAM 01.01 study).

  Anticancer research 20060101

• Successful management of cerebral and pulmonary mucormycosis with liposomal amphotericin B in a 28-year-old woman with acute lymphoblastic leukemia.

  Acta bio-medica : Atenei Parmensis 20060101

• Mitoxantrone-associated acute myelogenous leukemia in a patient with high-risk adenocarcinoma of the prostate: a case report and brief review.

  Cancer investigation 20060101

• [Remission in T-cell prolymphocytic leukemia during the FMC treatment course].

  Terapevticheskii arkhiv 20060101

• Efficacy of mitoxantrone and intrathecal triamcinolone acetonide treatment in chronic progressive multiple sclerosis patients.

  Clinical neuropharmacology 20060101

• In vivo effects of mitoxantrone on the production of pro- and anti-inflammatory cytokines by peripheral blood mononuclear cells of secondary progressive multiple sclerosis patients.

  Neuroimmunomodulation 20060101

• Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.

  Oncology 20060101

• Mitoxantrone treatment of multiple sclerosis: safety considerations.

  Neurology 20051227

• A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.

  Cancer 20051215

• Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report.

  Leukemia 20051201

• Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation.

  Apoptosis : an international journal on programmed cell death 20051201

• BCRP transports dipyridamole and is inhibited by calcium channel blockers.

  Pharmaceutical research 20051201

• [Therapy of hormone-refractory prostate cancer].

  Der Urologe. Ausg. A 20051201

• Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance.

  Cancer research 20051201

• Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051201

• Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051201

• The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.

  Haematologica 20051201

• [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].

  Ai zheng = Aizheng = Chinese journal of cancer 20051201

• Therapeutic options in androgen-independent prostate cancer: building on docetaxel.

  BJU international 20051201

• Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B.

  Haematologica 20051201

• Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.

  Oncogene 20051117

• Piperazinobenzopyranones and phenalkylaminobenzopyranones: potent inhibitors of breast cancer resistance protein (ABCG2).

  Journal of medicinal chemistry 20051117

• [What was the cause of fever, neck pain and arm paresis? Normal blood picture led to error].

  MMW Fortschritte der Medizin 20051110

• Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2.

  The Journal of biological chemistry 20051104

• Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro.

  Journal of neuroimmunology 20051101

• Assessment of ATM phosphorylation on Ser-1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser-139-histone H2AX phosphorylation, cell cycle phase, and apoptosis.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20051101

• Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases.

  The Journal of urology 20051101

• Systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma.

  Journal of neuro-oncology 20051101

• Mitoxantrone in the treatment of multiple sclerosis.

  International MS journal 20051101

• Mitoxantrone for multiple sclerosis.

  The Cochrane database of systematic reviews 20051019

• Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.

  Journal of neurology 20051001

• Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia.

  Leukemia research 20051001

• Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.

  Oncology reports 20051001

• Rapid collapse of mitochondrial transmembrane potential in HL-60 cells and isolated mitochondria treated with anti-tumor 1,4-anthracenediones.

  Anti-cancer drugs 20051001

• Expression level of ABCG2 in the placenta decreases from the mid stage to the end of gestation.

  Bioscience, biotechnology, and biochemistry 20051001

• Routine application of the proton-pump inhibitor pantoprazole in patients with gastric lymphoma undergoing chemotherapy.

  Scandinavian journal of gastroenterology 20051001

• Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.

  Neurology 20050913

• A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.

  Annals of hematology 20050901

• Hetero-association of anticancer antibiotics in aqueous solution: NMR and molecular mechanics analysis.

  Biophysical chemistry 20050901

• High-dose mitoxantrone-vinblastine-cyclophosphamide and autologous stem cell transplantation for stage III breast cancer: final results of a prospective multicentre study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050901

• Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.

  Leukemia research 20050901

• Pilot study of tandem high-dose chemotherapy and autologous stem cell transplantation with a novel combination of regimens in patients with poor risk lymphoma.

  Bone marrow transplantation 20050901

• Effect of notch ligands on in vitro sensitivity to chemo-therapeutic drugs in leukemia and lymphoma cells.

  Oncology reports 20050901

• A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma.

  International journal of radiation oncology, biology, physics 20050901

• [Hormone-refractory metastatic prostate carcinoma -- combination improves survival].

  Aktuelle Urologie 20050901

• Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.

  Clinical lymphoma & myeloma 20050901

• Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050820

• [Treatment of refractory and relapsed acute lymphocytic leukemia in adults].

  Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 20050818

• Use of MLL/GRAF fusion mRNA for measurement of minimal residual disease during chemotherapy in an infant with acute monoblastic leukemia (AML-M5).

  Genes, chromosomes & cancer 20050801

• Interaction of anticancer drug mitoxantrone with DNA analyzed by electrochemical and spectroscopic methods.

  Biophysical chemistry 20050801

• Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.

  Drug metabolism and disposition: the biological fate of chemicals 20050801

• A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation.

  Bone marrow transplantation 20050801

• Gemcitabine and mitoxantrone in metastatic breast cancer: a phase-I-study.

  Investigational new drugs 20050801

• Preliminary investigation of mitoxantrone coating on stent-grafts to inhibit neointimal proliferation.

  Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists 20050801

• Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators.

  Cancer research 20050801

• The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.

  Urology 20050801

• [Therapy of hormone refractory prostate cancer: new standards, new trends].

  Aktuelle Urologie 20050801

• Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer.

  Internal medicine journal 20050801

• Multiplicity adjustment for multiple endpoints in clinical trials with multiple doses of an active treatment.

  Statistics in medicine 20050730

• [Multiple sclerosis--update].

  Praxis 20050727

• Effects of peroxidase substrates on the Amplex red/peroxidase assay: antioxidant properties of anthracyclines.

  Analytical biochemistry 20050715

• Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen.

  Cancer 20050715

• Characterization of ABCG2 gene amplification manifesting as extrachromosomal DNA in mitoxantrone-selected SF295 human glioblastoma cells.

  Cancer genetics and cytogenetics 20050715

• Modulation of breast cancer resistance protein mediated atypical multidrug resistance using RNA interference delivered by adenovirus.

  Chinese medical journal 20050705

• [Magnetic Drug Targeting--a new approach in locoregional tumor therapy with chemotherapeutic agents. Experimental animal studies].

  HNO 20050701

• [Magnetic drug targeting. New paths for the local concentration of drugs for head and neck cancer].

  HNO 20050701

• Transport of anthracyclines and mitoxantrone across membranes by a flip-flop mechanism.

  Biochemical pharmacology 20050701

• Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status.

  Internal medicine journal 20050701

• Prolonging survival in prostate cancer: chemotherapy will have an important role.

  BJU international 20050701

• Article on mitoxantrone-induced extravasation raised useful questions.

  Oncology nursing forum 20050701

• Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy.

  Leukemia & lymphoma 20050701

• Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy.

  Leukemia & lymphoma 20050701

• Granulocytic sarcoma of the heart: extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone.

  Leukemia & lymphoma 20050701

• Severe toxicity following induction chemotherapy for acute myelogenous leukemia in a patient with Werner's syndrome.

  Leukemia & lymphoma 20050701

• Extranodal mantle cell lymphoma in a prolapsed ileostomy stump.

  British journal of haematology 20050701

• Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer.

  Lancet (London, England) 20050701

• Changing the way we think about chronic lymphocytic leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050620

• Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050620

• Promoted electron transfer of mitoxantrone binding with DNA by cytochrome c.

  Biochemical and biophysical research communications 20050617

• Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.

  Blood 20050615

• Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial.

  Annals of hematology 20050601

• Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.

  Leukemia 20050601

• [The effect of combined mitoxantrone and methylprednisolone therapy in primary and secondary progressive multiple sclerosis. An applied study in 65 patients].

  Der Nervenarzt 20050601

• Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050601

• High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia.

  Leukemia 20050601

• High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants.

  American journal of clinical oncology 20050601

• Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2.

  Cancer research 20050601

• Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050601

• The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.

  Urology 20050601

• Future directions in the treatment of androgen-independent prostate cancer.

  Urology 20050601

• An interdisciplinary approach to treating prostate cancer.

  Urology 20050601

• High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an 'Intergruppo Italiano Linfomi' randomized trial.

  Haematologica 20050601

• A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20050601

• [Structure charateristics of mitoxantrone transforsomes].

  Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi 20050601

• Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients.

  Leukemia & lymphoma 20050601

• Mitoxantrone in secondarily progressive multiple sclerosis: a series of 18 patients.

  Arquivos de neuro-psiquiatria 20050601

• Acute myeloid leukaemia induced by mitoxantrone: case report.

  Arquivos de neuro-psiquiatria 20050601

• Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050520

• The application of enhanced parallel gatekeeping strategies.

  Statistics in medicine 20050515

• Secretory transport of irinotecan metabolite SN-38 across isolated intestinal tissue.

  Cancer chemotherapy and pharmacology 20050501

• Update in the management of patients with hormone-refractory prostate cancer.

  Current opinion in urology 20050501

• Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-beta.

  Journal of neuroimmunology 20050501

• Chemotherapy agents and timing of chemotherapy in prostate cancer management.

  Current urology reports 20050501

• Immunosuppressive therapy in multiple sclerosis.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20050501

• The current role of chemotherapy in metastatic hormone-refractory prostate cancer.

  Urology 20050501

• Knee arthritis as a rare inaugural manifestation of adult leukemia.

  Rheumatology international 20050501

• A practical approach to immunomodulatory therapy for multiple sclerosis.

  Physical medicine and rehabilitation clinics of North America 20050501

• [Hormonoresistant metastatic prostate cancer: analysis of two phase III clinical studies].

  Bulletin du cancer 20050501

• Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis.

  Expert review of neurotherapeutics 20050501

• Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study.

  Blood 20050415

• DNA topoisomerase II in therapy-related acute promyelocytic leukemia.

  The New England journal of medicine 20050414

• Expression and function of ABCB1 and ABCG2 in human placental tissue.

  Drug metabolism and disposition: the biological fate of chemicals 20050401

• Changes in adsorption and permeability of mitoxantrone on plasma membrane of BCRP/MXR resistant cells.

  Biochemical and biophysical research communications 20050401

• In vitro assessment of cytotoxic agent combinations for hormone-refractory prostate cancer treatment.

  Anti-cancer drugs 20050401

• Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2.

  Journal of cell science 20050401

• Multiple bilateral parotid sialoliths in a patient with mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) of the salivary glands.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20050401

• Selective gene silencing of rat ATP-binding cassette G2 transporter in an in vitro blood-brain barrier model by short interfering RNA.

  Journal of neurochemistry 20050401

• Molecular basis of the low activity of antitumor anthracenediones, mitoxantrone and ametantrone, in oxygen radical generation catalyzed by NADH dehydrogenase. Enzymatic and molecular modelling studies.

  European journal of medicinal chemistry 20050401

• Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.

  Cancer research 20050401

• Induction of the ABC-transporters Mdr1/P-gp (Abcb1), mrpl (Abcc1), and bcrp (Abcg2) during establishment of multidrug resistance following exposure to mitoxantrone.

  Journal of chemotherapy (Florence, Italy) 20050401

• Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma.

  Journal of neuro-oncology 20050401

• Which drug combination for hormone-refractory prostate cancer?

  Expert opinion on pharmacotherapy 20050401

• Design, synthesis and structure-activity relationships of novel taxane-based multidrug resistance reversal agents.

  Journal of medicinal chemistry 20050324

• Cyclosporin A is a broad-spectrum multidrug resistance modulator.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050315

• Breast cancer resistance protein in drug resistance of primitive CD34+38- cells in acute myeloid leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050315

• Prognostic features for response and survival in elderly patients with de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine.

  Leukemia & lymphoma 20050301

• Acute myeloid leukemia in the elderly: etoposide when anthracyclins are contraindicated.

  Leukemia & lymphoma 20050301

• Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.

  Cancer 20050301

• Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050301

• An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, Stage III or IV, low-grade non-Hodgkin lymphoma.

  Cancer 20050301

• Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050301

• Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy.

  European journal of cancer (Oxford, England : 1990) 20050301

• Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci.

  British journal of haematology 20050301

• [Current and new therapeutic strategies in acute myeloid leukemia].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050301

• Toxicity of the topoisomerase II inhibitors.

  Expert opinion on drug safety 20050301

• [Adams-Stokes attack due to complete atrioventricular block in a patient with acute promyelocytic leukemia during remission induction therapy using all-trans retinoic acid].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20050301

• A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma.

  Cancer 20050215

• Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.

  Cancer research 20050215

• Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface.

  The Journal of biological chemistry 20050211

• Topoisomerase II inhibitors, irrespective of their chemical composition, ameliorate experimental arthritis.

  Rheumatology (Oxford, England) 20050201

• Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20050201

• Effective treatment of indolent non-hodgkin's lymphomas with mitoxantrone, chlorambucil and prednisone.

  Onkologie 20050201

• Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050201

• The role of mitoxantrone in the treatment of indolent lymphomas.

  The oncologist 20050201

• Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model.

  Molecular cancer therapeutics 20050201

• [Chemotherapy for prostate cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20050201

• Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.

  The Canadian journal of urology 20050201

• Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?

  Nature clinical practice. Oncology 20050201

• Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?

  Nature clinical practice. Oncology 20050201

• Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer.

  Future oncology (London, England) 20050201

• Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050120

• Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050120

• Cloning and functional analysis of the rhesus macaque ABCG2 gene. Forced expression confers an SP phenotype among hematopoietic stem cell progeny in vivo.

  The Journal of biological chemistry 20050114

• Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.

  The Journal of pharmacology and experimental therapeutics 20050101

• Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients.

  Clinical and experimental immunology 20050101

• Induction chemotherapy for acute myelogenous leukemia.

  Current hematology reports 20050101

• High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol.

  European journal of cancer (Oxford, England : 1990) 20050101

• A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050101

• [VNCOP-B (etoposide, mitoxantrone, cyclophosphamide, vincristine, predonisolone, bleomycin) therapy in elderly patients with aggressive non-Hodgkin lymphoma--a study of efficacy and safety, final report].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050101

• Complete remissions in chemotherapy of lung cancer models induced in mice by asbestos.

  The Mount Sinai journal of medicine, New York 20050101

• Mitoxantrone-induced extravasation.

  Oncology nursing forum 20050101

• Separation of liposome-entrapped mitoxantrone from nonliposomal mitoxantrone in plasma: pharmacokinetics in mice.

  Methods in enzymology 20050101

• Hypoxia-induced acidification causes mitoxantrone resistance not mediated by drug transporters in human breast cancer cells.

  Cellular oncology : the official journal of the International Society for Cellular Oncology 20050101

• Preparation, characterization, and stability of liposome-based formulations of mitoxantrone.

  Drug development and industrial pharmacy 20050101

• Acute demyelination: an insight into the effect of mitoxantrone on CNS lesions.

  Journal of neuroradiology. Journal de neuroradiologie 20050101

• Modulation of BCRP mediated atypical multidrug resistance phenotype by RNA interference.

  Neoplasma 20050101

• Case reports: mitozantrone-induced onycholysis associated with subungual abscesses, paronychia, and pyogenic granuloma.

  Journal of drugs in dermatology : JDD 20050101

• Methylxanthines (caffeine, pentoxifylline and theophylline) decrease the mutagenic effect of daunomycin, doxorubicin and mitoxantrone.

  Acta biochimica Polonica 20050101

• Mitoxantrone therapy in rapidly worsening multiple sclerosis.

  Bratislavske lekarske listy 20050101

• Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis.

  European neurology 20050101

• Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma.

  Oncology 20050101

• Anthracyclines.

  Cancer chemotherapy and biological response modifiers 20050101

• Impact of uncertainty on cost-effectiveness analysis of medical strategies: the case of high-dose chemotherapy for breast cancer patients.

  International journal of technology assessment in health care 20050101

• Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.

  Neoplasma 20050101

• Acute myeloid leukemia treatment in patients over 60 years of age. Comparison of symptomatic, palliative, and aggressive therapy.

  Neoplasma 20050101

• [Chemotherapy of hormone-resistent cancer of the prostate].

  Urologiia (Moscow, Russia : 1999) 20050101

• Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?

  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20050101

• Proteomic evidence for roles for nucleolin and poly[ADP-ribosyl] transferase in drug resistance.

  Journal of proteome research 20050101

• [A structural and thermodynamic analysis of novatrone and flavin mononucleotide heteroassociation in aqueous solution by 1H NMR spectroscopy].

  Bioorganicheskaia khimiia 20050101

• Celiac axis infusion and microembolization for advanced stage III/IV pancreatic cancer--a phase II study on 265 cases.

  Anticancer research 20050101

• Unbiased examination of changes in plasma membrane proteins in drug resistant cancer cells.

  Journal of proteome research 20050101

• Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL.

  Roczniki Akademii Medycznej w Bialymstoku (1995) 20050101

• [Mantle cell lymphoma mimicking chronic lymphocytic leukemia].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20050101

• Mechanism of action of mitoxantrone.

  Neurology 20041228

• Review of mitoxantrone in the treatment of multiple sclerosis.

  Neurology 20041228

• Mitoxantrone for multiple sclerosis in clinical practice.

  Neurology 20041228

• Mitoxantrone treatment of multiple sclerosis: safety considerations.

  Neurology 20041228

• Identifying and treating patients with suboptimal responses.

  Neurology 20041228

• Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis.

  Neurology 20041228

• Current approved options for treating patients with multiple sclerosis.

  Neurology 20041228

• Synthesis and biological evaluation of new 1,5-diazaanthraquinones with cytotoxic activity.

  Bioorganic & medicinal chemistry 20041215

• Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041215

• Strategies for managing the side effects of treatments for multiple sclerosis.

  Neurology 20041214

• Multidrug transporter activity in lymphocytes.

  British journal of pharmacology 20041201

• Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041201

• Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer.

  International journal of radiation oncology, biology, physics 20041201

• Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study.

  Leukemia & lymphoma 20041201

• [Chemotherapy for hepatocellular carcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20041201

• Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference.

  Molecular cancer therapeutics 20041201

• [Biodistribution of N-(2-hydroxypropyl) methacrylamide copolymer-bound mitoxantrone in mice bearing Ehrlich solid tumor].

  Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi 20041201

• Multiple sclerosis.

  Clinical evidence 20041201

• A RasGAP-derived cell permeable peptide potently enhances genotoxin-induced cytotoxicity in tumor cells.

  Oncogene 20041125

• Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes.

  Oncogene 20041125

• [Immunomodulatory therapy in multiple sclerosis].

  Ideggyogyaszati szemle 20041120

• The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.

  Blood 20041115

• Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.

  Blood 20041101

• Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041101

• High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors.

  Leukemia & lymphoma 20041101

• Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041101

• In vitro cytotoxicity of mitoxantrone-incorporated albumin microspheres on acute promyelocytic leukaemia cells.

  Journal of microencapsulation 20041101

• Antitumour antibiotic containing regimens for metastatic breast cancer.

  The Cochrane database of systematic reviews 20041018

• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

  The New England journal of medicine 20041007

• Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

  The New England journal of medicine 20041007

• Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adults.

  Leukemia research 20041001

• Phase II study of PEND chemotherapy in patients with refractory/relapsed Hodgkin lymphoma.

  Leukemia & lymphoma 20041001

• Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents.

  Expert opinion on pharmacotherapy 20041001

• [Expression establishment and functional analysis of breast cancer resistance protein with doxycycline induced tet regulating system in mouse fibroblast cell line PA317].

  Ai zheng = Aizheng = Chinese journal of cancer 20041001

• Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.

  Molecular cancer therapeutics 20041001

• [Pseudomonas sepsis with ecthyma gangrenosum in an acute myeloid leukemia patient].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20041001

• [Clinical study on mitoxantrone contained regimen for treatment of newly diagnosed childhood acute lymphoblastic leukemia].

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20041001

• Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells.

  Oncogene 20040916

• Is there a role for chemotherapy in prostate cancer?

  British journal of cancer 20040913

• Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone.

  Leukemia 20040901

• The effectiveness and practicality of immunosuppressive drugs.

  International MS journal 20040901

• Direct assessment of drug penetration into tissue using a novel application of three-dimensional cell culture.

  Cancer research 20040901

• Second-line chemotherapy for hormone-refractory prostate cancer: has the time come?

  Clinical prostate cancer 20040901

• [Therapy of painful bone metastases in patients with prostate carcinoma. The AP 32/02 Study of the AUO].

  Der Urologe. Ausg. A 20040901

• A nurse-led, patient-centred mitoxantrone service in neurology.

  British journal of nursing (Mark Allen Publishing) 20040901

• Mechanisms of mitoxantrone in multiple sclerosis--what is known?

  Journal of the neurological sciences 20040815

• Rationale for the use of mitoxantrone in multiple sclerosis.

  Journal of the neurological sciences 20040815

• The argument against the use of cyclophosphamide and mitoxantrone in the treatment of multiple sclerosis.

  Journal of the neurological sciences 20040815

• Autologous hemopoietic stem cell transplantation in the treatment of multiple sclerosis: rationale and clinical experience.

  Journal of the neurological sciences 20040815

• Clinical practice of immunosuppressive treatments in multiple sclerosis: results of a second international questionnaire.

  Journal of the neurological sciences 20040815

• Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity.

  Journal of the neurological sciences 20040815

• Reversible paraneoplastic neuropathy associated with T-cell large granular lymphocyte leukemia.

  Neurology 20040810

• Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte-derived soluble factor(s).

  Journal of neurochemistry 20040801

• Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice.

  Journal of neuroimmunology 20040801

• Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20040801

• Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20040801

• [Mobilization of peripheral blood stem cells with mitoxantrone and high-dose cytarabine chemotherapy and rhG-CSF in patients with hematopoietic malignancies].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20040801

• Surface-enhanced Raman scattering reveals adsorption of mitoxantrone on plasma membrane of living cells.

  Biochemical and biophysical research communications 20040723

• Primary adrenal lymphoma presenting as Addison's disease: case report and review of the literature.

  Annals of hematology 20040701

• HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).

  The Journal of pharmacology and experimental therapeutics 20040701

• Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.

  Haematologica 20040701

• Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study.

  Gynecologic oncology 20040701

• [Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040701

• IgD kappa myeloma: a new case.

  Joint, bone, spine : revue du rhumatisme 20040701

• Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport.

  Pharmaceutical research 20040701

• Intralesional mitoxantrone biopolymer-mediated chemotherapy prolongs survival in rats with experimental brain tumors.

  Journal of neuro-oncology 20040701

• Presentation of extramedullary acute myelogenous leukemia as bilateral testicular masses: response to non-myeloablative allogeneic transplantation.

  Leukemia & lymphoma 20040701

• Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy.

  Canadian journal of physiology and pharmacology 20040701

• Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.

  Cancer 20040615

• Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation.

  British journal of cancer 20040614

• A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.

  Leukemia research 20040601

• Treatment of a well differentiated pulmonary adenocarcinoma in a cat by pneumonectomy and adjuvant mitoxantrone chemotherapy.

  Journal of feline medicine and surgery 20040601

• Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy.

  International journal of oncology 20040601

• Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis.

  Journal of neuroimmunology 20040601

• Health outcomes in multiple sclerosis.

  Current opinion in neurology 20040601

• Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040601

• Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20040601

• [Chemotherapy of the hormone-refractory prostate cancer].

  Aktuelle Urologie 20040601

• Acute myeloid leukaemia induced by mitoxantrone in a multiple sclerosis patient.

  Journal of neurology 20040601

• A modified low-dose regimen of mitoxantrone and prednisolone in patients with androgen-independent prostate cancer.

  Japanese journal of clinical oncology 20040601

• Fludarabine, cyclophosphamide and mitoxantrone for untreated follicular lymphoma: a report from the non-Hodgkin's lymphoma co-operative study group.

  Leukemia & lymphoma 20040601

• A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia.

  Hematological oncology 20040601

• Priming with granulocyte colony-stimulating factor--relation to high-dose cytarabine in acute myeloid leukemia.

  The New England journal of medicine 20040520

• Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023.

  Cancer chemotherapy and pharmacology 20040501

• The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells.

  Experimental cell research 20040501

• Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport.

  Molecular pharmacology 20040501

• Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.

  Cancer research 20040501

• Heart transplantation in a patient with multiple sclerosis and mitoxantrone-induced cardiomyopathy.

  The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20040501

• Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.

  Haematologica 20040501

• Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone.

  International journal of hematology 20040501

• Bendamustine plus mitoxantrone--a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study.

  Leukemia & lymphoma 20040501

• Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.

  Leukemia & lymphoma 20040501

• [Selective tumor-accumulation of HPMA copolymer-mitoxantrone conjugates].

  Yao xue xue bao = Acta pharmaceutica Sinica 20040501

• Disease-modifying drugs for the early treatment of multiple sclerosis.

  Expert review of neurotherapeutics 20040501

• A molecular understanding of mitoxantrone-DNA adduct formation: effect of cytosine methylation and flanking sequences.

  The Journal of biological chemistry 20040430

• Interaction of the breast cancer resistance protein with plant polyphenols.

  Biochemical and biophysical research communications 20040423

• Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.

  The Prostate 20040401

• Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20040401

• A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis.

  Expert opinion on pharmacotherapy 20040401

• Rituximab in a patient with acute renal failure due to B-cell lymphomatous infiltration of the kidneys.

  Leukemia & lymphoma 20040401

• [Postoperative intraperitioneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20040401

• Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin's lymphoma.

  Clinical advances in hematology & oncology : H&O 20040401

• Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040315

• Determination of the in vivo effects of cladribine alone and its combination with cyclophosphamide or cyclophosphamide and mitoxantrone on Bax and Bcl-2 protein expression in B-CLL cells.

  Oncology reports 20040301

• The study of mitoxantrone as a potential immunosuppressor in transgenic pig renal xenotransplantation in baboons: comparison with cyclophosphamide.

  Xenotransplantation 20040301

• Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients.

  British journal of haematology 20040301

• Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review.

  European journal of cancer (Oxford, England : 1990) 20040301

• Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine.

  Anti-cancer drugs 20040301

• Successful treatment of disseminated nasal T-cell lymphoma using high-dose chemotherapy and autologus peripheral blood stem cell transplantation: a case report.

  Auris, nasus, larynx 20040301

• [Primary studies on synthesis and properties of mitoxantrone-insulin conjugates].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20040301

• Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040215

• [Multiple sclerosis (MS), an inflammatory or degenerative disease?].

  Presse medicale (Paris, France : 1983) 20040214

• [Aggressive multiple sclerosis. Definition and specific therapeutic indication].

  Presse medicale (Paris, France : 1983) 20040214

• Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.

  Cancer chemotherapy and pharmacology 20040201

• Marginal effects of regional intra-arterial chemotherapy as an alternative treatment option in advanced pancreatic carcinoma.

  Langenbeck's archives of surgery 20040201

• Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study.

  American journal of clinical oncology 20040201

• Second malignancies after chemotherapy and radiotherapy for Hodgkin disease.

  American journal of clinical oncology 20040201

• Gastrointestinal stromal tumours (Br J Surg 2003; 90: 1178-1186).

  The British journal of surgery 20040201

• Therapy related acute myeloblastic leukaemia after mitoxantrone treatment in a patient with multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20040201

• Urinary immunocytology for primary bladder B cell lymphoma.

  Urology 20040201

• Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial.

  British journal of haematology 20040201

• [Radiation and concomitant chemotherapy after surgery for breast cancer].

  Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 20040201

• Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells.

  Oncogene 20040129

• Suppressing immunity in advancing MS: too much too late, or too late for much?

  Neurology 20040127

• Improved liquid chromatographic method for mitoxantrone quantification in mouse plasma and tissues to study the pharmacokinetics of a liposome entrapped mitoxantrone formulation.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040105

• Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93.

  Leukemia 20040101

• Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.

  International journal of cancer 20040101

• Children with acute myeloblastic leukemia presenting with extramedullary infiltration: the effects of high-dose steroid treatment.

  Leukemia research 20040101

• The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis.

  Clinical and experimental immunology 20040101

• VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040101

• Treatment of Marburg variant multiple sclerosis with mitoxantrone.

  Journal of neuroimaging : official journal of the American Society of Neuroimaging 20040101

• Pleurodesis for malignant pleural effusions.

  The Cochrane database of systematic reviews 20040101

• [Antitumor activity of mitoxantrone-nanosphere against murine liver tumor H22].

  Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20040101

• Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer--a phase II trial.

  Prostate cancer and prostatic diseases 20040101

• Piroxicam, mitoxantrone, and coarse fraction radiotherapy for the treatment of transitional cell carcinoma of the bladder in 10 dogs: a pilot study.

  Journal of the American Animal Hospital Association 20040101

• Repeated rituximab maintenance courses in fludarabine-failed young patients with chronic lymphocytic leukaemia responding to FAND chemotherapy.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Fludarabine, mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed, low-grade non-Hodgkin's lymphomas with unfavorable prognostic factors: results of a phase II study.

  Leukemia & lymphoma 20040101

• Mitoxantrone: a review of its use in multiple sclerosis.

  CNS drugs 20040101

• Maintenance therapy in childhood acute myeloid leukemia.

  Annals of hematology 20040101

• Adjuvant intravesical mitoxantrone versus recombinant interferon-alpha after transurethral resection of superficial bladder cancer: a randomized prospective study.

  Urologia internationalis 20040101

• A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases.

  Journal of gastroenterology 20040101

• Formation of mitoxantrone adducts in human tumor cells: potentiation by AN-9 and DNA methylation.

  Oncology research 20040101

• Parental longevity and prognosis in elderly patients with aggressive non-Hodgkin's lymphoma.

  Acta oncologica (Stockholm, Sweden) 20040101

• Highly altered protein expression profile in the adriamycin resistant MCF-7 cell line.

  Journal of proteome research 20040101

• Intravenous immunoglobulin and mitoxantrone stop the progression of secondary progressive multiple sclerosis in a patient with interferon intolerance.

  Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) 20040101

• Effective knock down of very high ABCG2 expression by a hammerhead ribozyme.

  Anticancer research 20040101

• Paclitaxel and mitoxantrone in metastatic breast cancer: a phase II trial of the Italian Oncology Group for Cancer Research.

  Cancer investigation 20040101

• 2-Chlorodeoxyadenosine alone and in combination with cyclophosphamide and mitoxantrone induce apoptosis in B chronic lymphocytic leukemia cells in vivo.

  Cancer detection and prevention 20040101

• [Evaluation of the clinical effectivity and toxicity of the FDN regimen (fludarabin, mitoxantron, dexamethason) in patients with follicular lymphoma].

  Casopis lekaru ceskych 20040101

• [Evaluation of the long term effect of mitoxantrone on neurological disability in patients with active multiple sclerosis].

  Srpski arhiv za celokupno lekarstvo 20040101

• [The multidrug tumor cell resistance phenotype caused by the impaired cell death program].

  Vestnik Rossiiskoi akademii meditsinskikh nauk 20040101

• [Use of fludarabin in conjunction with other cytostatics in the treatment of non-Hodgkin lymphoma resistant to standard chemotherapy].

  Voprosy onkologii 20040101

• Treatment options in hormone-refractory metastatic prostate carcinoma.

  Tumori 20040101

• Mitoxantrone (Novantrone) in multiple sclerosis: new insights.

  Expert review of neurotherapeutics 20040101

• 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20031215

• Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20031215

• Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A.

  International journal of cancer 20031210

• Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.

  International journal of cancer 20031210

• Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP).

  Annals of oncology : official journal of the European Society for Medical Oncology 20031201

• Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.

  Cancer 20031201

• Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.

  Bone marrow transplantation 20031201

• Hematopoietic cells from mice that are deficient in both Bcrp1/Abcg2 and Mdr1a/1b develop normally but are sensitized to mitoxantrone.

  BioTechniques 20031201

• Chloroma of the orbit in a non-leukemic adult: A case report.

  Orbit (Amsterdam, Netherlands) 20031201

• MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia.

  International journal of hematology 20031201

• [Acute heart failure in a patient treated by mitoxantrone for multiple sclerosis].

  Revue neurologique 20031201

• [Mitoxantrone chemoprophylaxis for multirecurrent multifocal superficial bladder tumours: results of a phase 2 controlled study].

  Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 20031201

• Highlights from the XII European Cancer Conference Copenhagen, Denmark.

  Clinical prostate cancer 20031201

• New approach in delivering chemotherapy: locoregional treatment for recurrent glioblastoma (rGBM).

  Journal of experimental & clinical cancer research : CR 20031201

• The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

  Neurology 20031125

• Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.

  Annals of hematology 20031101

• Non-invasive functional and biochemical assessment of mitoxantrone cardiotoxicity in patients with multiple sclerosis.

  Journal of cardiovascular pharmacology 20031101

• Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation.

  Leukemia 20031101

• The role of breast cancer resistance protein in acute lymphoblastic leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20031101

• Synthesis and characterization of the tumor targeting mitoxantrone-insulin conjugate.

  Archives of pharmacal research 20031101

• Low L-selectin (CD62L) expression in acute myeloid leukemia correlates with a bad cytogenetic risk.

  European journal of haematology 20031101

• Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia.

  Leukemia & lymphoma 20031101

• Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents.

  Biochemical pharmacology 20031001

• [Mitoxanthrone in the therapy of multiple sclerosis].

  Der Nervenarzt 20031001

• Inhibition of induced chemoresistance by cotreatment with (E)-5-(2-bromovinyl)-2'-deoxyuridine (RP101).

  Cancer research 20030915

• New and emerging treatment options for multiple sclerosis.

  The Lancet. Neurology 20030901

• Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030901

• Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation.

  Biochemical pharmacology 20030901

• The effect of mitoxantrone on anti-pig immunization in baboons.

  Xenotransplantation 20030901

• Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.

  Cancer research 20030901

• Extramedullary acute myeloid leukemia (granulocytic sarcoma) with arm paresis, maculopapular exanthema and organ involvement.

  Leukemia & lymphoma 20030901

• Non-Hodgkin's lymphoma presenting as a giant chest wall mass.

  Leukemia & lymphoma 20030901

• Rituximab in heavily pretreated cutaneous B-cell lymphoma.

  Leukemia & lymphoma 20030901

• Mitoxantrone-cyclophosphamide-rituximab: an effective and safe combination for indolent NHL.

  Hematological oncology 20030901

• Efficacy of mitoxantrone-loaded albumin microspheres for intratumoral chemotherapy of breast cancer.

  Journal of controlled release : official journal of the Controlled Release Society 20030828

• Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia.

  Blood 20030815

• Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030801

• Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial.

  Leukemia 20030801

• Expression and functional analyses of breast cancer resistance protein in lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030801

• Therapy-related leukemia in mitozantrone treated patients.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20030801

• [Newer disease--modifying drugs: glatiramer acetate and mitoxantrone].

  Nihon rinsho. Japanese journal of clinical medicine 20030801

• [Immunologic therapy for secondary and primary progressive multiple sclerosis].

  Nihon rinsho. Japanese journal of clinical medicine 20030801

• Oxidation of mitoxantrone by lactoperoxidase.

  Biochimica et biophysica acta 20030730

• Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup.

  Blood 20030715

• Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).

  Blood 20030715

• Clinical effects of combination therapy with mitoxantrone, vincristine, and prednisolone in breast cancer.

  Cancer chemotherapy and pharmacology 20030701

• Intraperitoneal chemotherapy with mitoxantrone in malignant ascites.

  Surgical oncology clinics of North America 20030701

• Chemotherapy of prostate cancer: present and future.

  Current urology reports 20030601

• Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia.

  Leukemia 20030601

• Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.

  Leukemia 20030601

• High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence.

  Cancer 20030601

• The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.

  Urology 20030601

• First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial.

  Clinical lymphoma 20030601

• The potential effect of short-course high-dose steroid on the maturation and apoptosis of leukemic cells in a child with acute megakaryoblastic leukemia.

  Leukemia & lymphoma 20030601

• Multiple paradigm shifts in multiple sclerosis.

  Current opinion in neurology 20030601

• Current disease-modifying therapies in multiple sclerosis.

  Seminars in neurology 20030601

• [Diagnosis and treatment of multiple sclerosis. Update, 2003].

  MMW Fortschritte der Medizin 20030526

• CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial.

  Blood 20030515

• Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030515

• Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire?

  Leukemia research 20030501

• The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells.

  International journal of oncology 20030501

• Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.

  The Journal of urology 20030501

• Acute myelogenous leukemia following mitoxantrone treatment for multiple sclerosis.

  The Annals of pharmacotherapy 20030501

• Randomized multicentric study of perioperative chemotherapy with mitoxantrone in early breast cancer.

  Annals of surgical oncology 20030501

• A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis.

  Leukemia 20030501

• Electrochemical determination of interaction parameters for DNA and mitoxantrone in an irreversible redox process.

  Biophysical chemistry 20030501

• Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS.

  Neurology 20030422

• Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia.

  Leukemia research 20030401

• Relevance of drug uptake, cellular distribution and cell membrane fluidity to the enhanced sensitivity of Down's syndrome fibroblasts to anticancer antibiotic-mitoxantrone.

  Biochimica et biophysica acta 20030401

• [Mitoxantrone, a new reality].

  Revista de neurologia 20030401

• Partially successful treatment of a patient with chronic lymphocytic leukemia and Hodgkin's disease: case report and literature review.

  American journal of hematology 20030401

• Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats.

  Journal of neurosurgery 20030401

• [Drug-resistant proteins in breast cancer: recent progress in multidrug resistance].

  Ai zheng = Aizheng = Chinese journal of cancer 20030401

• Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.

  Cancer chemotherapy and pharmacology 20030401

• A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma.

  Leukemia & lymphoma 20030401

• Intrapericardial instillation of mitoxantrone in palliative therapy of malignant pericardial effusion.

  Onkologie 20030401

• Magnetic drug targeting--biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment.

  Journal of drug targeting 20030401

• Mitoxantrone trial in multiple sclerosis.

  Lancet (London, England) 20030329

• Investigation on the interaction of DNA and electroactive ligands using a rapid electrochemical method.

  Journal of biochemical and biophysical methods 20030328

• A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival.

  Blood 20030315

• Association of genomic imbalances with drug resistance and thermoresistance in human gastric carcinoma cells.

  International journal of cancer 20030301

• [Adjuvant and additive therapy for cancer of the pancreas].

  Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 20030301

• Application of a human multidrug transporter (ABCG2) variant as selectable marker in gene transfer to progenitor cells.

  Human gene therapy 20030301

• Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20030301

• Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer.

  British journal of cancer 20030224

• Synthesis and biological evaluation of 2,7-Dihydro-3H-dibenzo[de,h]cinnoline-3,7-dione derivatives, a novel group of anticancer agents active on a multidrug resistant cell line.

  Bioorganic & medicinal chemistry 20030220

• Mitoxantrone in progressive multiple sclerosis: when and how to treat?

  Journal of the neurological sciences 20030215

• Interferon beta-1a in primary progressive multiple sclerosis.

  Journal of the neurological sciences 20030215

• A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030201

• Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030201

• The last to die is hope: prolonged mechanical circulatory support with a Novacor left ventricular assist device as a bridge to transplantation.

  The Journal of thoracic and cardiovascular surgery 20030201

• Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor.

  BJU international 20030201

• Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab.

  Annals of hematology 20030201

• Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20030201

• Severe heart failure in a young multiple sclerosis patient.

  Journal of neurology 20030201

• Serial gadolinium-enhanced MRI in acute attack of multiple sclerosis treated with plasma exchange.

  Journal of neurology 20030201

• Rituximab plus chemotherapy in follicular and mantle cell lymphomas.

  Seminars in oncology 20030201

• A randomized trial comparing intravesical instillations of mitoxantrone and doxorubicin in patients with superficial bladder cancer.

  Chang Gung medical journal 20030201

• A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis.

  Clinical therapeutics 20030201

• Saccharomyces cerevisiae as an eukaryotic cell model to assess cytotoxicity and genotoxicity of three anticancer anthraquinones.

  Mutagenesis 20030101

• Recent advances in pediatric acute lymphoblastic and myeloid leukemia.

  Current opinion in oncology 20030101

• Treatment of large cell lymphoma in elderly patients with a mitoxantrone, cyclophosphamide, etoposide, and prednisone regimen: long-term follow-up results.

  Cancer 20030101

• NOVP chemotherapy for Hodgkin's disease transiently induces sperm aneuploidies associated with the major clinical aneuploidy syndromes involving chromosomes X, Y, 18, and 21.

  Cancer research 20030101

• Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists.

  Molecular cancer therapeutics 20030101

• Treatment of multiple sclerosis and related disorders: what's new in the past 2 years?

  Clinical neuropharmacology 20030101

• Multiple sclerosis. Treatment is shifting.

  Mayo Clinic health letter (English ed.) 20030101

• Effects of mitoxantrone on multiple sclerosis patients' lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10.

  European neurology 20030101

• A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT).

  Annals of oncology : official journal of the European Society for Medical Oncology 20030101

• Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma.

  The hematology journal : the official journal of the European Haematology Association 20030101

• [Analysis of causes of death during intensive chemotherapy according to treatment protocol AML-BFM 93].

  Klinische Padiatrie 20030101

• High-risk localized prostate cancer: primary surgery and adjuvant therapy.

  Urologic oncology 20030101

• Regional celiac artery infusion in the adjuvant treatment of pancreatic cancer.

  Anticancer research 20030101

• [Mitoxantrone].

  Neurologia (Barcelona, Spain) 20030101

• New principles in the treatment of prostate cancer--the oncologist's view.

  Scandinavian journal of urology and nephrology. Supplementum 20030101

• Mitoxantrone mediates demethylation and reexpression of cyclin d2, estrogen receptor and 14.3.3sigma in breast cancer cells.

  Cancer biology & therapy 20030101

• Mitoxantrone: a hypomethylating agent?

  Cancer biology & therapy 20030101

• Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone.

  Anticancer research 20030101

• DNA damage induced by DNA topoisomerase I- and topoisomerase II-inhibitors detected by histone H2AX phosphorylation in relation to the cell cycle phase and apoptosis.

  Cell cycle (Georgetown, Tex.) 20030101

• First-line intra-arterial chemotherapy (IAC) with epirubicin and mitoxantrone in locally advanced breast cancer.

  Anticancer research 20030101

• The interaction of daunorubicin and mitoxantrone with the red blood cells of acute myeloid leukemia patients.

  Cellular & molecular biology letters 20030101

• Immunosuppressive antimetabolites inhibit induction of contact hypersensitivity while lymphoablative drugs also prevent its expression.

  European journal of dermatology : EJD 20030101

• High-dose chemotherapy with mitoxantrone + melphalan and autologous stem cell rescue in metastatic breast cancer patients: a study of feasibility and tolerability.

  Tumori 20030101

• Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.

  Blood 20021215

• Low levels of ABCG2 expression in adult AML blast samples.

  Blood 20021215

• Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation.

  The Journal of biological chemistry 20021213

• ABCG2 confers resistance to indolocarbazole compounds by ATP-dependent transport.

  Biochemical and biophysical research communications 20021213

• Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study.

  Blood 20021201

• Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer.

  The Journal of urology 20021201

• Editorial: States and state transitions are all that really matter.

  The Journal of urology 20021201

• Issues and practices in multiple sclerosis.

  Neurorehabilitation and neural repair 20021201

• Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia.

  British journal of haematology 20021201

• Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.

  Bone marrow transplantation 20021201

• Adjuvant intraperitoneal chemotherapy with cisplatinum, mitoxantrone, 5-fluorouracil, and calcium folinate in patients with gastric cancer: a phase II study.

  American journal of clinical oncology 20021201

• [Immunosuppressive medication in multiple sclerosis].

  Revista de neurologia 20021201

• Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.

  Lancet (London, England) 20021201

• Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas.

  Leukemia & lymphoma 20021201

• Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects.

  Internal medicine journal 20021101

• Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial.

  Annals of oncology : official journal of the European Society for Medical Oncology 20021101

• Blast crisis of chronic myeloid leukemia: diagnosis prompted by T(8;9).

  Journal of pediatric hematology/oncology 20021101

• Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats.

  Journal of neurosurgery 20021101

• Treatment of secondary myelodysplastic syndrome after heart transplantation with chemotherapy and nonmyeloablative stem-cell transplantation.

  Transplantation 20021027

• [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].

  Deutsche medizinische Wochenschrift (1946) 20021025

• Inhibition of basal and transforming growth factor-beta-induced stimulation of COL1A1 transcription by the DNA intercalators, mitoxantrone and WP631, in cultured human dermal fibroblasts.

  The Journal of biological chemistry 20021011

• Visual recovery in a man with the rare combination of mtDNA 11778 LHON mutation and a MS-like disease after mitoxantrone therapy.

  Acta neurologica Scandinavica 20021001

• Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial.

  Blood 20021001

• Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation.

  Blood 20021001

• Efficacy and tolerance of a scalp-cooling system for prevention of hair loss and the experience of breast cancer patients treated by adjuvant chemotherapy.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20021001

• A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20021001

• CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: results by demographic and clinical subgroups.

  American journal of clinical oncology 20021001

• Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary study.

  Gynecologic oncology 20021001

• Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

  Neurology 20020924

• Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS.

  Neurology 20020924

• Key issues in the diagnosis and treatment of multiple sclerosis. An overview.

  Neurology 20020924

• Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BCRP/ABCP/ABCG2.

  Biochimica et biophysica acta 20020920

• Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.

  European journal of cancer (Oxford, England : 1990) 20020901

• Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia.

  Blood 20020901

• Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients.

  Annals of oncology : official journal of the European Society for Medical Oncology 20020901

• Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group.

  British journal of haematology 20020901

• Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients.

  Haematologica 20020901

• Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.

  Haematologica 20020901

• Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis.

  American journal of hematology 20020901

• Chemotherapy for prostate cancer.

  Urology 20020901

• Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia.

  Annals of hematology 20020901

• A phase II study of dose-dense docetaxel and mitoxantrone in the treatment of patients with high-risk metastatic breast cancer.

  Anti-cancer drugs 20020901

• Updated meta analysis finds that interferon-alpha improves progression-free and overall survival in low-grade non-Hodgkin's lymphoma when administered with chemotherapy that contains anthracycline or mitoxantrone.

  Clinical lymphoma 20020901

• Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma.

  Clinical lymphoma 20020901

• Overexpression of the atypical protein kinase C zeta reduces topoisomerase II catalytic activity, cleavable complexes formation, and drug-induced cytotoxicity in monocytic U937 leukemia cells.

  The Journal of biological chemistry 20020830

• Primary squamous cell carcinoma of the prostate: a novel chemotherapy regimen.

  The Journal of urology 20020801

• Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model.

  The Journal of urology 20020801

• Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years.

  Haematologica 20020801

• A relapsed non-Hodgkin lymphoma presenting as panhypopituitarism successfully treated by chemotherapy.

  Journal of neuro-oncology 20020801

• [Immunosuppressants and multiple sclerosis].

  Revista de neurologia 20020801

• Segmental coecal cytomegalovirus colitis during fludarabine, cytarabine and mitoxantrone induction chemotherapy for myelodysplastic syndrome.

  Leukemia & lymphoma 20020801

• Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2.

  Cancer gene therapy 20020701

• Monitoring, and estimation of kinetic data, by piezoelectric impedance analysis, of the binding of the anticancer drug mitoxantrone to surface-immobilized DNA.

  Analytical and bioanalytical chemistry 20020701

• Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.

  American journal of hematology 20020701

• beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells.

  Experimental hematology 20020701

• Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells.

  Journal of cancer research and clinical oncology 20020701

• Quantitative analysis of mitoxantrone by surface-enhanced resonance Raman scattering.

  Analytical chemistry 20020701

• Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment.

  European journal of haematology 20020701

• Conjunctival chloroma (granulocytic sarcoma).

  Lancet (London, England) 20020629

• A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents.

  Biochemistry 20020625

• [Experience with fludarabine treatment and review of the literature].

  Orvosi hetilap 20020616

• Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020615

• Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies.

  Anti-cancer drugs 20020601

• Flexible low-intensity combination chemotherapy for elderly patients with acute myeloid leukemia.

  International journal of hematology 20020601

• Flow cytometric analysis of breast cancer resistance protein expression and function.

  Cytometry 20020601

• Phase III trial of a humanized anti-CD33 antibody (HuM195) in patients with relapsed or refractory acute myeloid leukemia.

  Clinical lymphoma 20020601

• Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.

  Clinical lymphoma 20020601

• Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro.

  European journal of haematology 20020601

• Methotrexate-associated liver toxicity in a patient with breast cancer: case report and literature review.

  The Netherlands journal of medicine 20020601

• C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.

  Molecular cancer therapeutics 20020601

• [Preparation of long circulating mitoxantrone liposomes and its pharmacokinetics].

  Yao xue xue bao = Acta pharmaceutica Sinica 20020601

• Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia.

  Blood 20020515

• Myocardial function in patients with multiple sclerosis treated with low-dose mitoxantrone.

  The American journal of cardiology 20020515

• Outcomes in patients treated with gemtuzumab ozogamicin for relapsed acute myelogenous leukemia.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20020515

• Occupational asthma due to mitoxantrone.

  Allergy 20020501

• Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.

  Cancer chemotherapy and pharmacology 20020501

• Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia.

  Leukemia 20020501

• Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels.

  Leukemia & lymphoma 20020501

• Considerations in the treatment of relapsing-remitting multiple sclerosis.

  Neurology 20020423

• High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020415

• Anthracyclines in the treatment of gynecologic malignancies.

  Gynecologic oncology 20020401

• Results of an international questionnaire on immunosuppressive treatment of multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20020401

• The role of mitoxantrone in non-Hodgkin's lymphoma.

  Oncology (Williston Park, N.Y.) 20020401

• CNOP for diffuse aggressive non-Hodgkin's lymphoma: the Nebraska lymphoma study group experience.

  Leukemia & lymphoma 20020401

• A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation.

  Bone marrow transplantation 20020401

• Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

  Molecular cancer therapeutics 20020401

• European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease.

  Cancer 20020315

• Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells.

  Cytokine 20020307

• Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas.

  Leukemia research 20020301

• Intraperitoneal mitoxantrone: a feasibility and pharmacokinetic study.

  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20020301

• Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.

  Japanese journal of cancer research : Gann 20020301

• Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma.

  Clinical lymphoma 20020301

• Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.

  European journal of haematology 20020301

• Alphabet soup: a personal, evolving, mostly evidence-based and logical, sequential approach to the 'ABCNR' drugs in multiple sclerosis.

  Seminars in neurology 20020301

• Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.

  International journal of cancer 20020220

• The modulation by xanthines of the DNA-damaging effect of polycyclic aromatic agents. Part II. The stacking complexes of caffeine with doxorubicin and mitoxantrone.

  Biochemical pharmacology 20020215

• Chemotherapeutic stress mediated by certain antitumor antibiotics induces an atypical CD69+ surface phenotype in peripheral T-lymphocytes.

  International immunopharmacology 20020201

• Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020201

• A prolonged APTT in a patient with a low grade malignant NHL - a case report.

  Haematologica 20020201

• Hematopoietic cell transplantation beyond first remission.

  Leukemia 20020201

• Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone.

  Seminars in oncology 20020201

• Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study.

  Cancer 20020201

• Therapeutic approaches to secondary progressive multiple sclerosis.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20020201

• [Value of mitoxantrone in metastatic hormone-resistant prostate cancer].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20020201

• [Role of mitoxantrone in the treatment of hormone-independent metastatic cancer of the prostate].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20020201

• Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas.

  Leukemia & lymphoma 20020201

• Induction of apoptosis by cladribine (2-CdA), gemcitabine and other chemotherapeutic drugs on CD34+/CD38+ and CD34+/CD38- hematopoietic progenitor cells: selective effects of doxorubicin and 2-CdA with protection of immature cells.

  Leukemia & lymphoma 20020201

• Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma.

  European journal of haematology 20020201

• Acute lymphocytic leukemia CNS disease presenting as central diabetes insipidus.

  The Journal of the Association of Physicians of India 20020201

• Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.

  Neurology 20020122

• In vivo analysis of human multidrug resistance protein 1 (MRP1) activity using transient expression of fluorescently tagged MRP1.

  Cancer research 20020115

• c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for mitoxantrone- and anisomycin-induced apoptosis in HL-60 cells.

  Leukemia research 20020101

• Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.

  Blood 20020101

• Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.

  Haematologica 20020101

• The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020101

• Controversies in chemotherapy of prostate cancer.

  Frontiers of radiation therapy and oncology 20020101

• Philadelphia chromosome-positive acute myeloid leukemia with tetraploidy.

  International journal of hematology 20020101

• Experience with methotrexate, 5-fluorouracil, and leucovorin (MFL): a first line effective, minimally toxic regimen for metastatic breast cancer.

  Cancer investigation 20020101

• Assessment of response by breast helical computed tomography to neoadjuvant chemotherapy in large inflammatory breast cancer.

  Clinical breast cancer 20020101

• Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group.

  Leukemia & lymphoma 20020101

• Treatment of non-Hodgkin's lymphoma in the elderly. The Italian studies.

  Tumori 20020101

• Treatment of elderly Hodgkin's lymphoma patients. The experience of the Italian Lymphoma Intergroup.

  Tumori 20020101

• The effect of doxorubicin and its analogue mitoxantrone on cardiac muscle and on serum lipids: an experimental study.

  Anticancer research 20020101

• Timed sequential chemotherapy with concomitant granulocyte colony-stimulating factor for high-risk acute myelogenous leukemia: a single arm clinical trial.

  BMC cancer 20020101

• Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management.

  CNS drugs 20020101

• [Thermodynamic analysis of interaction of mitoxantrone with deoxytetranucleotide 5'-d(TpGpCpA) in the water solution based on 1H-NMR spectrophotometry].

  Biofizika 20020101

• ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial.

  Annals of oncology : official journal of the European Society for Medical Oncology 20020101

• Binding free energy of selected anticancer compounds to DNA--theoretical calculations.

  Journal of molecular modeling 20020101

• Lactic acid based PEU/HA and PEU/BCP composites: Dynamic mechanical characterization of hydrolysis.

  Journal of biomedical materials research 20020101

• A comparison of the in vitro genotoxicity of anticancer drugs idarubicin and mitoxantrone.

  Acta biochimica Polonica 20020101

• Inv(4)(p14q27) in a case with de novo acute nonlymphocytic leukemia.

  Acta haematologica 20020101

• CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside.

  Acta haematologica 20020101

• The antineoplastic treatment in the elderly.

  La Clinica terapeutica 20020101

• [Effect of intercalators on the properties of liquid-crystalline dispersions of nucleic acid-chitosan complex].

  Molekuliarnaia biologiia 20020101

• [Post-marketing surveillance information transmitted via electronic mail in a University Hospital].

  Therapie 20020101

• A long-term survival case underwent repeated hepatic arterial infusion chemotherapy with portal branch ligation and wrapping of the liver using sheets for hepatocellular carcinoma.

  Hepato-gastroenterology 20020101

• Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisolone.

  Haematologia 20020101

• Acute myelogenous leukaemia in older patients at St Bartholomew's Hospital: outcome with mitoxantrone and cytarabine.

  The hematology journal : the official journal of the European Haematology Association 20020101

• P-glycoprotein expression by cancer cells affects cell cytotoxicity and cell-cycle perturbations induced by six chemotherapeutic drugs.

  Journal of experimental therapeutics & oncology 20020101

• Loss of growth factor sensitivity and development of mitoxantrone resistance in transplanted recurrent SA7HD myeloid leukemia.

  Journal of experimental therapeutics & oncology 20020101

• Evaluation of the in vitro cytotoxicity of mitoxantrone following repeated freeze-thaw cycles.

  Veterinary therapeutics : research in applied veterinary medicine 20020101

• Paclitaxel and mitoxantrone in the treatment of metastatic breast cancer: a phase II trial of the Minnie Pearl Cancer Research Network.

  Cancer investigation 20020101

• The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients - a report of Polish Acute Leukemia Group (PALG) phase II study.

  Neoplasma 20020101

• Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group.

  Blood 20011215

• Locally advanced primary breast cancer: medium-term results of a randomised trial of multimodal therapy versus initial hormone therapy.

  European journal of cancer (Oxford, England : 1990) 20011201

• A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011201

• Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival.

  Cancer 20011201

• A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.

  Acta neurologica Belgica 20011201

• Unrelated cord blood transplantation for an infant with chemotherapy-resistant progressive Langerhans cell histiocytosis.

  Journal of pediatric hematology/oncology 20011201

• [Recent therapeutic strategy for multiple sclerosis].

  Rinsho shinkeigaku = Clinical neurology 20011201

• High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: a Phase II multicentric trial.

  Cancer 20011115

• Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.

  Gynecologic oncology 20011101

• Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy.

  Bone marrow transplantation 20011101

• Primary progressive multiple sclerosis.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20011101

• Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.

  Blood 20011015

• Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma.

  Cancer 20011015

• Hydrogels for combination delivery of antineoplastic agents.

  Biomaterials 20011001

• Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia.

  Leukemia 20011001

• In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials?

  Leukemia 20011001

• Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis.

  Leukemia 20011001

• [Combination chemotherapy with VP-16 in the treatment of lung cancer and malignant lymphoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20011001

• Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.

  Oncology (Williston Park, N.Y.) 20011001

• Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.

  Bone marrow transplantation 20011001

• The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity.

  Cancer chemotherapy and pharmacology 20011001

• Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders.

  Annals of oncology : official journal of the European Society for Medical Oncology 20011001

• FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.

  European journal of haematology 20011001

• Intracavitary therapies for mesothelioma.

  Current treatment options in oncology 20011001

• Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells.

  Blood 20010915

• Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.

  Cancer research 20010915

• University of Washington high-dose cyclophosphamide, mitoxantrone, and etoposide experience in metastatic breast cancer: unexpected cardiac toxicity.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010915

• [New approaches in research of therapy of multiple sclerosis].

  Medizinische Klinik (Munich, Germany : 1983) 20010915

• Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.

  Blood 20010901

• Cost-effectiveness analysis with risk aversion.

  Health economics 20010901

• Establishment of two vaccine-associated feline sarcoma cell lines and determination of in vitro chemosensitivity to doxorubicin and mitoxantrone.

  American journal of veterinary research 20010901

• Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.

  Japanese journal of cancer research : Gann 20010901

• Prostate cancer in the older man.

  Oncology (Williston Park, N.Y.) 20010901

• [Comparison of the effectiveness of idarubicin (Zavedos) and mitoxantrone (Refador) in induction therapy of acute myeloid leukemia in elderly patients (55-75) (a prospective multicenter randomized study conducted 1998-2000].

  Vnitrni lekarstvi 20010901

• Enhanced expression of human ABC-transporter tap is associated with cellular resistance to mitoxantrone.

  FEBS letters 20010817

• Resistance to topoisomerase poisons due to loss of DNA mismatch repair.

  International journal of cancer 20010815

• A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia.

  Blood 20010815

• A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.

  Cancer research 20010815

• The DNA helicase activity of yeast Sgs1p is essential for normal lifespan but not for resistance to topoisomerase inhibitors.

  Mechanisms of ageing and development 20010801

• Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine.

  Blood 20010801

• CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized multicenter study.

  American journal of clinical oncology 20010801

• Treatment of aggressive non-Hodgkin's lymphoma in elderly patients with thiotepa, Novantrone (mitoxantrone), vincristine, prednisone (TNOP).

  American journal of clinical oncology 20010801

• Treatment of hormone refractory prostate cancer.

  Seminars in urologic oncology 20010801

• Can chemotherapy alter the course of prostate cancer?

  Seminars in urologic oncology 20010801

• Complications of chemotherapy for prostate cancer.

  Seminars in urologic oncology 20010801

• Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.

  Onkologie 20010801

• Perioperative locoregional application of mitoxantrone in patients with early breast carcinoma.

  Journal of chemotherapy (Florence, Italy) 20010801

• Amifostine does not inhibit the toxic effects of anthracycline derivates or mitoxantrone on MDR tumor cell lines.

  Leukemia & lymphoma 20010801

• Mitoxantrone: new indication. More risky than beneficial in advanced prostate cancer.

  Prescrire international 20010801

• Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours.

  Journal of neuro-oncology 20010801

• Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins.

  Cancer research 20010715

• Detection of human herpesvirus 6 and JC virus in progressive multifocal leukoencephalopathy complicating follicular lymphoma.

  American journal of hematology 20010701

• Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas.

  International journal of radiation oncology, biology, physics 20010701

• Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.

  European journal of haematology. Supplementum 20010701

• Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant.

  European journal of haematology. Supplementum 20010701

• Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin's lymphoma: a pilot study.

  Annals of hematology 20010701

• Incremental net benefit in randomized clinical trials.

  Statistics in medicine 20010615

• A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2).

  Biochimica et biophysica acta 20010606

• Esters of 2-(1-hydroxyalkyl)-1,4-dihydroxy-9,10-anthraquinones with melphalan as multifunctional anticancer agents.

  Bioorganic & medicinal chemistry letters 20010604

• Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer.

  European journal of cancer (Oxford, England : 1990) 20010601

• Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma.

  Leukemia 20010601

• The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.

  Leukemia 20010601

• Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.

  Leukemia 20010601

• Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.

  Annals of hematology 20010601

• A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010601

• Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010601

• Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens.

  Journal of experimental & clinical cancer research : CR 20010601

• From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance.

  Cellular and molecular life sciences : CMLS 20010601

• Paclitaxel and docetaxel in prostate cancer.

  Hematology/oncology clinics of North America 20010601

• Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO.

  Blood 20010515

• Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010515

• Cytosine methylation enhances mitoxantrone-DNA adduct formation at CpG dinucleotides.

  The Journal of biological chemistry 20010511

• Atp-bound topoisomerase ii as a target for antitumor drugs.

  The Journal of biological chemistry 20010511

• Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia.

  Leukemia 20010501

• Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010501

• Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer.

  Bone marrow transplantation 20010501

• Acute metabolic alkalosis enhances response of C3H mouse mammary tumors to the weak base mitoxantrone.

  Neoplasia (New York, N.Y.) 20010501

• Immunologic therapy for relapsing-remitting multiple sclerosis.

  Current neurology and neuroscience reports 20010501

• Immunologic therapy for secondary and primary progressive multiple sclerosis.

  Current neurology and neuroscience reports 20010501

• HPV16-E6 enhances mitoxantrone sensitivity in a human ovarian cancer line: an isolated instance or a trend?

  International journal of oncology 20010401

• Complications associated with intraperitoneal chemotherapy catheters.

  Gynecologic oncology 20010401

• Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study.

  American journal of clinical oncology 20010401

• Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness.

  Expert opinion on pharmacotherapy 20010401

• High remission rate in acute myeloblastic leukemia with only two days of chemotherapy.

  Leukemia & lymphoma 20010401

• Acute promyelocytic leukemia with additional chromosome abnormalities in a renal transplant case.

  Annals of hematology 20010401

• Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.

  Bone marrow transplantation 20010401

• Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma.

  Haematologica 20010301

• Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model.

  British journal of cancer 20010301

• Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.

  Anti-cancer drugs 20010301

• Neutrophilic eccrine hidradenitis in two neutropaenic patients.

  Clinical and experimental dermatology 20010301

• Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study.

  Annals of hematology 20010301

• Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance-associated ABC transporter BCRP/MXR/ABCG2.

  Cancer gene therapy 20010301

• Cemp, a mitoxantrone containing combination, in the treatment of intermediate and high grade non-hodgkin's lymphoma: an effective and non toxic therapeutic alternative for adult and elderly patients.

  Leukemia & lymphoma 20010301

• Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia.

  European journal of haematology 20010301

• Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.

  European journal of haematology 20010301

• Secondary leukemia after adjuvant chemotherapy for breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010215

• Anthracycline adjuvant chemotherapy: how much is enough?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010201

• Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010201

• Elderly ovarian cancer: treatment with mitoxantrone-carboplatin.

  Gynecologic oncology 20010201

• [Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?].

  Revista espanola de medicina nuclear 20010201

• Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor.

  American journal of clinical oncology 20010201

• High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity.

  Leukemia 20010201

• Induction therapy of adult acute lymphocytic leukemia without the use of vincristine or prednisone.

  Hematology/oncology clinics of North America 20010201

• [Escalating immunomodulatory therapy of multiple sclerosis. 1st supplement: December 2000].

  Der Nervenarzt 20010201

• Multiple sclerosis treatment 2001.

  Neurologic clinics 20010201

• [Conjugation of mitoxantrone-loaded nanospheres and anti-C-erbB-2 monoclonal antibodies].

  Yao xue xue bao = Acta pharmaceutica Sinica 20010201

• Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines.

  Bioorganic & medicinal chemistry letters 20010108

• Chemotherapy and marrow transplantation for congenital leukaemia.

  Archives of disease in childhood. Fetal and neonatal edition 20010101

• DNA-interactive anticancer aza-anthrapyrazoles: biophysical and biochemical studies relevant to the mechanism of action.

  Molecular pharmacology 20010101

• The role of laparoscopy in second-look evaluations for ovarian cancer.

  Gynecologic oncology 20010101

• Serum LDH, a prognostic factor in elderly patients with acute myelogenous leukaemia.

  British journal of cancer 20010101

• Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.

  British journal of haematology 20010101

• DNA topoisomerase II inhibition by peroxisomicine A(1) and its radical metabolite induces apoptotic cell death of HL-60 and HL-60/MX2 human leukemia cells.

  Chemical research in toxicology 20010101

• 5'-deoxy-5-fluorouridine, medroxyprogestrone acetate and mitoxantrone hydrochloride for advanced or recurrent breast cancer.

  Breast cancer (Tokyo, Japan) 20010101

• Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010101

• Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours.

  Cancer chemotherapy and pharmacology 20010101

• High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: a phase I trial.

  Bone marrow transplantation 20010101

• Clinical assessment of a chemosensitivity assay as a treatment planning tool for dogs with cancer.

  Journal of the American Animal Hospital Association 20010101

• The efficacy of combination chemotherapy including intraperitoneal cisplatinum and mitoxantrone with intravenous ifosfamide in patients with FIGO stage I C ovarian carcinoma.

  European journal of gynaecological oncology 20010101

• Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast cancer.

  Cancer investigation 20010101

• Combination therapy of percutaneous mitoxantrone injection, percutaneous ethanol injection, and transcatheter arterial embolization for intrahepatic hepatocellular carcinoma and adrenal metastasis.

  Hepato-gastroenterology 20010101

• Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.

  Journal of cancer research and clinical oncology 20010101

• Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group Study.

  American journal of hematology 20010101

• Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen.

  Leukemia & lymphoma 20010101

• A systematic overview of chemotherapy effects in acute myeloid leukaemia.

  Acta oncologica (Stockholm, Sweden) 20010101

• Intensive postremission chemotherapy in Taiwanese adults with acute myelogenous leukemia.

  Advances in therapy 20010101

• Pharmaco-economic study of intensive chemotherapy with peripheral blood progenitor cell support for advanced breast cancer.

  Oncology reports 20010101

• [Improved treatment results in children with AML: Results of study AML-BFM 93].

  Klinische Padiatrie 20010101

• Cladribine combined with mitoxantrone in the treatment of blastic phase of chronic myeloid leukemia.

  Neoplasma 20010101

• T-cell-rich B-cell lymphoma. Analysis of clinical features, response to treatment, survival and comparison with diffuse large B-cell lymphoma.

  Oncology 20010101

• Treatment options in hormone-refractory prostate cancer: current and future approaches.

  Drugs 20010101

• Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone.

  Anticancer research 20010101

• Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma.

  The hematology journal : the official journal of the European Haematology Association 20010101

• Drug helps delay progression of multiple sclerosis.

  FDA consumer 20010101

• Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity.

  Tumori 20010101

• Sinus bradycardia secondary to mitoxantrone.

  Missouri medicine 20000601

• Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.

  Cancer 20000501

• Sinus bradycardia due to mitoxantrone.

  Southern medical journal 20000401

• Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs.

  Cancer chemotherapy and pharmacology 20000101

• First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin.

  American journal of clinical oncology 19991201

• Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.

  Cancer research 19991201

• Toxicity of a particulate formulation for the intraperitoneal application of mitoxantrone.

  International journal of pharmaceutics 19990415

• Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy.

  Seminars in oncology 19980801

• Fas ligand is constitutively secreted by prostate cancer cells in vitro.

  Clinical cancer research : an official journal of the American Association for Cancer Research 19980701

• A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma.

  Bone marrow transplantation 19971101

• [Mitoxantrone-induced acute left heart failure after intrapleural administration].

  Herz 19970801

• S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes.

  Annals of hematology 19970501

• Mitoxantrone-induced bradycardia.

  Annals of internal medicine 19970301

• Pericarditis induced by high-dose cytosine arabinoside chemotherapy.

  Annals of hematology 19970101

• Cerebellar toxicity with medium-dose cytarabine in a young patient with renal insufficiency.

  American journal of hematology 19961101

• Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells.

  Cancer research 19961015

• Bradycardia due to mitoxantrone exacerbated by previous anthracycline therapy.

  American journal of hematology 19960801

• Therapy-related leukemia with a novel 21q22 rearrangement.

  Cancer genetics and cytogenetics 19960801

• [Severe 5-fluorouracil toxicity in a woman treated for breast cancer with concurrent osteogenesis imperfecta and dehydrogenase deficiency].

  Bulletin du cancer 19960401

• Expression of inducible nitric oxide synthase in failing and non-failing human heart.

  Journal of molecular and cellular cardiology 19960101

• Comparison of mitozantrone and epirubicin in advanced breast cancer.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 19960101

• Rhabdomyolysis: an unusual complication of cytotoxic chemotherapy.

  Medical oncology (Northwood, London, England) 19951201

• High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: a phase I clinical trial.

  Clinical cancer research : an official journal of the American Association for Cancer Research 19951201

• [Long-term selective beta 1-blockade therapy for a patient with anthracycline-induced cardiomyopathy].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 19951101

• Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.

  Journal of medicinal chemistry 19950317

• Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia.

  Leukemia 19940401

• Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement.

  Annals of oncology : official journal of the European Society for Medical Oncology 19940101

• High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells.

  Blood 19931115

• Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults.

  Leukemia & lymphoma 19931001

• Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 19930701

• [Superselective intra-arterial chemotherapy in breast cancer].

  Der Radiologe 19930501

• Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells.

  Cancer research 19930201

• A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome.

  European journal of cancer (Oxford, England : 1990) 19930101

• Intravesical mitoxantrone in superficial bladder tumours (Ta-T1).

  European journal of cancer (Oxford, England : 1990) 19930101

• Mitoxantrone (dihydroxyanthracenedione) in acute leukemia. An evaluation of two treatment schedules by the Southwest Oncology Group.

  Investigational new drugs 19930101

• Reversible cardiopathy after accidental overdose of mitoxantrone.

  Pediatric hematology and oncology 19930101

• Fulminant hepatic failure after high-dose cytosine arabinoside and mitoxantrone treatment for relapse of acute myelogenous leukaemia.

  European journal of haematology 19921001

• Phase II trial of mitoxantrone in head and neck carcinoma.

  American journal of clinical oncology 19910801

• A phase I trial of 14-day continuous intravenous infusion mitoxantrone.

  Anti-cancer drugs 19910601

• Ventricular late potentials in the assessment of mitoxantrone cardiotoxicity.

  Cardiology 19910101

• A phase I-II study of high-dose cyclophosphamide, thiotepa and escalating doses of mitoxantrone with autologous stem cell rescue in patients with refractory malignancies.

  Bone marrow transplantation 19901201

• High activity of daily-schedule mitoxantrone in newly diagnosed low-grade non-Hodgkin's lymphomas: a 5-year follow-up.

  Seminars in oncology 19901201

• [Even mitoxantrone can cause local skin necrosis].

  Lakartidningen 19900117

• Discoloration of the nails and early anemia after mitoxantrone, folinic acid and 5-fluorouracil.

  Medical oncology and tumor pharmacotherapy 19900101

• Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 19890501

• Warning against use of intrathecal mitoxantrone.

  Lancet (London, England) 19890401

• Mitoxantrone induced congestive heart failure in patients previously treated with anthracyclines.

  British journal of haematology 19890201

• Salvage of relapsed malignant histiocytosis by autologous bone marrow transplant.

  Bone marrow transplantation 19890101

• [Evaluation of ventricular function in patients treated with mitoxantrone and 4'-epidoxorubicin].

  Archivos del Instituto de Cardiologia de Mexico 19890101

• Evaluation of ventricular function by echocardiography and radionuclide angiography in patients treated with mitoxantrone.

  Drugs under experimental and clinical research 19890101

• Treatment of refractory or relapsed adult acute leukemia by using mitoxantrone-containing regimens.

  Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association 19890101

• Cardiotoxicity of mitozantrone assessed by stress and resting nuclear ventriculography.

  European journal of cancer & clinical oncology 19880501

• Primary chemotherapy with mitoxantrone and prednisone in advanced breast carcinoma. A phase II study.

  European journal of cancer & clinical oncology 19880301

• Mitoxantrone: an active, new antitumor agent with an improved therapeutic index.

  Cancer treatment reviews 19871201

• Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C).

  Investigational new drugs 19871201

• Mitoxantrone in the treatment of patients with non-Hodgkin's Lymphoma.

  Cancer treatment reports 19871201

• A case of mitozantrone-associated cardiomyopathy without prior anthracycline therapy.

  The British journal of radiology 19871101

• Combined mitoxantrone plus doxorubicin in the treatment of breast cancer.

  American journal of clinical oncology 19870801

• High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.

  Blood 19870301

• Paraplegia after intrathecal mitozantrone.

  Lancet (London, England) 19861213

• Reversible bilateral lateral rectus muscle palsy associated with high-dose cytosine arabinoside and mitoxantrone therapy.

  Cancer 19861015

• Inhibition of endogenous respiration in rat heart slices as a measure of mitoxantrone cardiac toxicity.

  Oncology 19860101

• Early and delayed clinical cardiotoxicity of doxorubicin.

  Cancer 19850615

• A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study).

  Investigational new drugs 19850101

• Fatal congestive heart failure following mitoxantrone treatment in two children previously treated with doxorubicin and cisplatin.

  Cancer treatment reports 19830101

• Comparison of cardiotoxicity of two anthracenediones and doxorubicin in rats.

  Toxicology letters 19820501